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Failed regeneration of myelin in the central nervous system (CNS) contributes 
to axon loss/ dysfunction in prevalent neurodegenerative disorders, for which 
there is an unmet need for effective therapies. Previous work from this lab has 
demonstrated that remyelination requires a transition in microglia activation 
from pro-inflammatory (inducible nitric oxide synthase (iNOS)+) to pro-
regenerative (arginase-1 (Arg-1+). However, the mechanisms underpinning 
microglia activation remain unknown, and the assumption that in	situ tissue 
macrophages can transition in activation state has never been substantiated. 
Here, unexpectedly it is revealed that microglia activation during remyelination 
is driven by their death and subsequent repopulation. More specifically, pro-
inflammatory microglia undergo controlled necrosis (necroptosis), followed by 
repopulation via residual microglia and CNS-resident Nestin+ cell 
differentiation into microglia. Blocking necroptosis prevented microglial death 
and maintained their pro-inflammatory (iNOS+) activation, which consequently 
hindered remyelination. In human brain tissue, necroptosing and repopulating 
microglia were only significantly increased in white matter lesions with a high 
potential for remyelination. These results overturn current assumptions that 
following injury, microglia simply switch their activation from an initial pro-
inflammatory phenotype to become pro-regenerative. Impairment in microglia 
death and/or repopulation may thus underpin the chronic pro-inflammatory 
microglia activation associated with failed remyelination in human pathology, 
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highlighting a novel therapeutic strategy in the treatment of chronic 




Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system 
(CNS) where the electrical insulation covering nerves (myelin) is destroyed in a 
process termed demyelination. Although in the early stages of MS, myelin can be 
repaired (remyelination), this eventually fails, leading to a progressive 
worsening of symptoms and an increase in disability. Currently there are no 
approved therapies aimed at promoting remyelination in MS, therefore greater 
knowledge of how remyelination takes place is needed in order to develop such 
therapies.  
Previous work from our lab has shown that the microglia, the immune cells of 
the brain, are important in driving remyelination; microglia respond initially to 
damage by becoming inflammatory, and later change to become anti-
inflammatory and promote repair of the myelin. In progressive MS, it has been 
suggested that this switch in microglia behaviour doesn’t take place, which 
results in failed remyelination. Therefore, uncovering how microglia change 
their behaviour to promote remyelination may represent a new therapeutic 
target for MS.  
Work from this thesis has shown that inflammatory microglia undergo cell 
death by a process called necroptosis.  Blocking inflammatory microglia from 
dying resulted in inflammatory microglia persisting, and this lead to a reduction 
in remyelination, suggesting that inflammatory microglia need to die for 
remyelination to take place.  
5 
 
Death of the inflammatory microglia leads to new microglia being generated 
from two sources; expansion of microglia that did not die, and stem cell-like 
cells becoming new microglia.  
Lastly, by looking at post-mortem brain tissue from MS patients, microglia 
undergoing necroptosis and repopulation are increased in areas of damage that 
have high potential for remyelination (active lesions), but not in lesions that 
have poor remyelination potential (inactive lesions). This would suggest that for 
remyelination to take place, inflammatory microglia must die in order for the 
activation of anti-inflammatory microglia to occur, which can help repair areas 
of damage. Furthermore, inflammatory microglia being resistant to dying may 
contribute to remyelination failure in progressive MS. Therefore, promoting 
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Microglia are the resident immune cells of the central nervous system (CNS). As 
part of the innate immune system, and accounting for as much as 12% and 16% 
of the total neural cells in the mouse and human brain, respectively (1,	2), 
microglia belong to a family of mononuclear phagocytes, which encompasses 
other tissue-resident macrophages, all CNS resident macrophages and 
monocyte derived cells (3). Microglia are the first line of defence for the CNS, 
constantly surveying the environment for signs of trauma or infection. Microglia 
are particularly sensitive to such changes, in part due to their ability to rapidly 
respond to ATP (released by dying cells) through their P2RY12 receptor (4), 
changes in extracellular potassium (indicating changes in neural activity) 
through their expression of sensitive potassium channels (5), and the detection 
of infection or injury by their expression of toll-like receptors (TLRs) (6). 
Although traditionally perceived as purely inflammatory cells, research from the 
last decade has uncovered previously underappreciated roles of microglia in 
inflammation resolution and tissue repair. In particular, microglia have been 
shown to promote remyelination (7,	8), the restoration of myelin around axons, 
which restores neural health and prevents neurodegeneration. Damage to 
myelin (demyelination) is a hallmark of multiple sclerosis (MS). Although 
remyelination can take place in early phases of MS, it is in the progressive phase 
of the disease where this process often fails, leading to neurodegeneration for 
which there is an unmet need for therapeutics. Furthermore, microglia show a 
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high degree of diversity and plasticity in their phenotype and function, and 
manipulation to promote a pro-repair phenotype may represent a novel 
therapeutic target for inflammatory and neurodegenerative diseases like MS. It 
is therefore important to uncover how microglia activation is orchestrated in 







Myelin is a lipid-rich sheath that wraps around axons in the peripheral (PNS) 
and central nervous systems (CNS). In the PNS, Schwann cells are the source of 
myelin, and each cell can myelinate one peripheral axon. In the CNS, 
oligodendrocytes are able to myelinate up to 50 axons each (9), therefore it is 
conceivable that damage to a single oligodendrocyte can have greater 
consequences than that of a single Schwann cell. Furthermore, repairing 
damage to myelin in the PNS is more rapid and efficient (10), as Schwann cells 
can remove myelin debris and dead cells before remyelinating the same axon 
(11), which oligodendrocytes do not have the capacity to do (9).   
The formation of myelin (myelination) in humans begins around gestational 
week (g.w.) 27 and continues well into early adulthood. Myelin was first 
discovered to provide electrical insulation to axons, enabling signals to be 
communicated faster by increasing the conduction velocity of the impulse. For 
example,  unmyelinated axons have conduction velocities that may reach 10 
meters per second (m/s), whereas myelinated axons can conduct at velocities 
up to 150 m/s (12).  Each myelin sheath is separated by a small gap along the 
axon called a Node of Ranvier, a voltage-dependent sodium channel-dense area 
where action potentials are propagated, enabling the electrical signal to travel 
rapidly between each sheath for faster (saltatory) conduction. Myelin has also 
been shown to provide trophic and metabolic support to the axon, including 
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lactate transfer from oligodendrocytes to the axon, essential for axonal Krebs 
cycle- dependent generation of ATP (13,	14). 
Myelin is comprised of approximately 80% lipid and 20% protein (9). The 
myelin proteins are comprised mainly of proteolipid protein (PLP), myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and myelin 
associated glycoprotein (MAG), each playing important roles in adhesion, 
structural support and wrap formation (15).  
Proper myelination is essential for nervous system development and function. 
Human diseases where myelin fails to develop properly including Pelizaeus-
Merzbacher disease (PMD) (and animal models of dysregulated myelin) have 
allowed for greater insight into the consequences of improper myelination on 
neural function and health. PMD is characterised by poor motor development 
and severe learning difficulties that begins in childhood, attributed to the failure 
of myelination and consequent axonal degeneration, often leading to death in 
late childhood (13). Therefore, myelin is vital for generation of rapid electrical 
signals through the axon and the maintenance of neural health and function.  
 
1.2.2.	Demyelination 
Given the importance of myelin in neural function and health, it is therefore not 
surprising that damage to myelin can be detrimental to the axon in a multitude 
of ways, leading to a range of pathological consequences. Demyelination is the 
loss of compact myelin, which can be caused by direct damage to the sheaths 
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themselves or by death of the oligodendrocyte, causing loss of saltatory 
conduction and therefore slower transmission of electrical signals, as well as 
loss of trophic and metabolic support to the axon (13).  Furthermore, 
demyelination causes a rapid redistribution of ion channels across the axon 
spreading out from the Nodes of Ranvier, leading eventually to Ca2+ influx, 
excitotoxicity, impairment of mitochondrial function and axon degeneration (13,	
16). 
Demyelination can be caused by many factors including exposure to 
environmental toxins like pesticides, genetic disorders, trauma and 
inflammation. Demyelination can have inflammatory and non-inflammatory 
causes and can be categorized as myelinoclastic where myelin is damaged by 
external factors, such as by exposure to toxins or inflammation, or 
leukodystrophic where inherited or spontaneous mutation leads to abnormal 
myelin development that degenerates.  Clinically, demyelination is often 
detected by magnetic resonance imaging (MRI), a medical imaging technique 
where grey matter (cell bodies) and white matter (myelin) of the brain and 
spinal cord can be distinguished based on differences of high water (grey 
matter) and high fat content (myelin). This principle therefore also allows for 
the detection of demyelinated areas in the white matter that appear as bright 





Remyelination is the reinstatement of myelin around a demyelinated axon. 
Efficient remyelination prevents axonal damage and loss, shown experimentally 
where remyelinated areas are associated with a lower incidence of axonal loss 
than areas of demyelination without repair (17‐19). Remyelination can also 
restore conduction velocity, shown by electrophysiological studies on 
remyelinated axons in the rat spinal cord and brainstem (20), and restore 
axonal function, as demyelination-induced paraplegia and blindness were 
reversed in cats that were allowed to recover from irradiation-induced 
demyelination (21).  
The development of models to study remyelination has improved our 
knowledge on the cellular and molecular mechanisms involved, as well as the 
potential to improve remyelination in diseases where it fails. Simplistic models 
involve inducing a focal demyelinating lesion in the CNS white matter, usually 
the corpus callosum or spinal cord, or globally to brain explant cultures, by 
using toxins that target myelin or the oligodendrocyte. The most widely used 
compounds are lysolecithin (LPC), to induce a focal demyelination of the mouse 
corpus callosum or spinal cord, and ethidium bromide to induce demyelination 
in the rat cerebellar peduncles. An advantage of focal lesioning is that a single 
demyelinating insult with these toxins produces a well-defined temporal 
response of remyelination that can be studied without ongoing (and 
confounding) demyelination. However, a major disadvantage of using these 
models is that they do not model the complexity of demyelinating diseases 
where there is ongoing demyelination and remyelination, nor do they model the 
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chronic inflammation that may also play a role in such diseases; therefore, they 
are not suitable as disease models, but nevertheless provide a great deal of 
insight into the mechanisms underpinning efficient remyelination.  More 
complex models of demyelination and remyelination include the cuprizone 
model, where oral treatment with the copper chelator causes a more global CNS 
demyelination in mice and rats (22). Similar to the other models, cuprizone 
produces a predictable time course of remyelination allowing for detailed study 
of molecular and cellular events during remyelination but differs slightly in that 
there is a phase of ongoing demyelination and remyelination that must be taken 
into account. Moreover, as cuprizone is supplemented into the chow of these 
animals, variabilities in the extent of demyelination between animals can occur 
depending on their food intake. Finally, experimental autoimmune 
encephalomyelitis, or EAE, is a model of CNS autoimmune-mediated 
inflammation and demyelination. This is achieved by injecting myelin proteins 
with an adjuvant to drive an autoimmune response, which leads to 
demyelination in the CNS. Although often mistaken for a model of MS, EAE does 
not recapitulate the full complexity of the disease, such as the heterogeneity 
presented in the human disease between patients and even between lesions. 
Furthermore, induction of disease in EAE is artificial, and most likely does not 
represent the initiation of disease in MS; indeed, clinical onset of symptoms in 
EAE is rapid, manifesting in days to weeks, yet it is thought that physiological 
processes that underlie MS go undetected for years before symptoms manifest 
(23). Nevertheless, EAE has been useful to understand some aspects of 
pathology such as acute and chronic lesion formation (19).    
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The stages of remyelination are now well characterised. In response to a 
demyelinating insult, oligodendrocyte progenitor cells (OPCs) need to migrate 
to the demyelinated lesion, proliferate to populate the lesion area, and finally 
differentiate into oligodendrocytes capable of producing new myelin sheaths 
(24). It has been shown that even if the oligodendrocyte survives, it does not 
have the ability to remyelinate the axon, as shown by transplantation of mature 
oligodendrocytes to demyelinated lesions (25), and therefore the recruitment of 
new OPCs to the lesion area is needed for remyelination to take place. Indeed, 
transplantation of progenitor cells into cuprizone-induced demyelinated brains 
irradiated of resident progenitor cells results in remyelination and a reduction 
of axonal damage compared to those without progenitor transplantation (17).  
Efficient remyelination relies on the presence of initial pro-proliferation cues, 
followed by distinct survival and differentiation cues. For example, tumour-
necrosis factor alpha (TNF-α), an inflammatory mediator released by immune 
cells like microglia, can promote OPC proliferation (26) but inhibits their 
differentiation (8), and is indeed secreted by microglia in the first few days 
following LPC-mediated demyelination  of the corpus callosum corresponding 
with the peak in OPC proliferation (8). OPC differentiation firstly involves 
maturation into pre-oligodendrocytes that contact the demyelinated axon, and 
then differentiation into oligodendrocytes that produce compact myelin around 
axons (24). It is during this time that the OPCs are particularly susceptible to 
death, and survival and differentiation cues such as insulin-like growth factor 
(IGF-1) (27), transforming growth factor beta (TGF-β) (28) and microglial 
secreted activin-A (8), are needed to maintain OPC survival, promote cell cycle 
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exit and differentiation. More recently, the growth regulatory protein CCN3 
which is secreted from regulatory T-cells has been shown to also promote 
oligodendrocyte differentiation and myelination in	vitro	(29). Therefore, 
efficient remyelination requires precise timing and coordination of OPC 
activation that is reliant on other neural cell responses, and disruption at any 




Diagram	1. Remyelination requires activation of OPCs. OPCs must become activated, 
migrate to the area of demyelination, proliferate, differentiate and mature into 






Multiple Sclerosis (MS) is an autoimmune disease characterised by chronic 
inflammation, demyelination and spontaneous remyelination that becomes less 
efficient over time (24). In the UK alone, around 100,000 people have MS, which 
affects women nearly 3 times more than men, and is usually diagnosed in young 
adulthood. Symptoms include visual, motor, sensory, and cognitive 
impairments. Although not fully understood, the causes of MS are attributed to a 
combination of environmental factors and genetic susceptibility. Such 
environmental factors include smoking (30), vitamin D deficiency (31) and 
previous viral infections, particularly infections with the Epstein-Barr virus 
(32). The genetic susceptibility of MS has been associated with allelic variations 
of the Major Histocompatibility Complex class II (MHC-II), molecules found on 
antigen-presenting cells of the immune system which are important for 
communicating with and initiating T-cell responses (33).   
There are three subtypes of MS: relapse-remitting (RRMS), secondary 
progressive (SPMS) and primary progressive (PPMS). 85% of patients have 
RRMS, which involves distinct attacks of symptoms (relapses) followed by 
complete or partial remission of symptoms that can repeat many times over 
decades. In roughly 70% of RRMS cases, recovery of symptoms does not take 
place, leading to a continuous worsening of symptoms and an increase in 
disability, progressing to secondary progressive (SPMS). In rare cases (10-
20%), patients will have a progressive disability from diagnosis, known as a 
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primary progressive form of the disease (PPMS). Although there are many drugs 
available to dampen inflammation and prevent relapses in RRMS, there has 
been less success in finding effective drugs to treat the progressive forms of MS, 
with Ocrelizumab being the only currently approved therapy PPMS.  
	
1.3.2.	Inflammation	and	demyelination	in	MS		
Along with the subtypes, MS can be split into two pathological phases; the first 
is associated with chronic inflammation, where ongoing demyelination and 
spontaneous remyelination occurs. Both primary and secondary progressive MS 
are less associated with inflammation but more with an increased and 
continuous loss of neurological function that is linked to failed remyelination 
and neurodegeneration. The initial causes of MS are unknown however two 
hypotheses have been proposed. Firstly the ‘outside-in’ hypothesis that suggests 
dysregulated peripheral immune activation, particularly T-cell driven responses 
lead to their migration into the CNS via disruptions in the blood brain barrier 
and their attack on myelin. Secondly, the ‘inside-out’ hypothesis suggests that 
degeneration to myelin occurs first, leading to an immune response that results 
in further degeneration and inflammation (34).  
As remyelination can take place in the early stages of MS, it is still not well 
understood why it inevitably fails as the disease progresses. Potential reasons 
have been proposed, including a failure of OPCs to be recruited (35), a depleted 
source of OPCs and a block in OPC differentiation; causes of which may be due 
to repeated bouts of demyelination depleting the progenitor pool (36) and the 
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chronic inflammatory environment preventing OPC differentiation (22). Indeed, 
tissue samples from some MS patients have shown by immunohistochemistry 
that there may be a lack of OPCs around demyelinated lesions (36). However, 
this is not always the case, as other studies have shown that demyelinated 
lesions in some patients are not associated with a lack of OPCs, but rather a 
failure of OPC differentiation (37,	38). Some patient lesions contain PLP+ pre-
myelinating oligodendrocytes that have undergone some degree of 
differentiation from OPCs, but a lack of MBP+ cells suggests that they but cannot 
fully differentiate into myelinating oligodendrocytes (39). The differences in 
patient findings highlight the heterogeneity and complexity of lesion formation 










Microglia were first identified in the 1880s by Franz Nissl, when the Nissl 
staining technique was developed, which lead to the conclusion that microglia 
were related to peripheral macrophages (40). Indeed, activated microglia were 
later observed by Victor Babes in 1897 after finding clusters of these cells in 
virally infected brain sections (40). It wasn’t until 1920 however, that Pio del 
Rio Hortega called these cells microglia. Rio Hortega went on to pioneer early 
microglia research, phenotypically characterising microglia in white matter 
during homeostasis and in response to lesion formation (40).  A century of 
research later, great advances in our knowledge of microglia ontogeny and 
function has highlighted the importance of microglia in CNS development, 
homeostasis and disease. Shown to be similar to peripheral macrophages, it was 
thought for decades that microglia shared a similar blood monocytic origin (41), 
however in recent years, lineage tracing studies have revealed microglia arise 
from precursor cells in the embryonic yolk sac (42).  Microglia have since been 
shown to have distinct transcriptional profiles in homeostasis and disease 
compared to their peripheral counterparts (43,	44), although they share 
functional similarities including antigen presentation, immune surveillance and 
phagocytosis (3).  For a long time the brain was thought to be an ‘immune 
privileged’ site, with microglia erroneously considered to be relatively 
quiescent, however recent live imaging techniques have uncovered that on the 
contrary, microglia are highly active during homeostasis, constantly surveying 
their local microenvironment by extending and contracting their processes (45,	
46). Furthermore, microglia are now appreciated to communicate with other 
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neural cell types, and are vital for efficient neurodevelopment and homeostasis 






Microglia appear in the blood islands of the mouse yolk sac at embryonic day 
(E) 9.0 and have been shown to populate the neuroepithelium by E9.5, prior to 
definitive haematopoiesis in the foetal liver and bone marrow (42,	49). 
Following the formation of the blood brain barrier (BBB) by E13.5, the migrated 
microglia become isolated from the periphery, yet they continue to populate the 
entire CNS via rapid proliferation from E10.5 up until birth, maturing into 
ramified microglia (50,	51). Early colonisation of microglia to the CNS is well 
conserved across vertebrates (52). In humans, IBA-1+ CD68+ CD45+ MHCII+ 
amoeboid microglia invade the cerebral cortex by g.w 4.5 (53,	54) and migrate 
to the immature white matter via the ventricular lumen and leptomeninges 
(53). A second wave of microglial infiltration at g.w 12-13 then seeds the 
embryonic brain via the vasculature (54). By g.w 22 microglia take on a ramified 
morphology and become fully mature by g.w 35. 
Microglia, unlike other tissue-resident macrophages, originate from 
erythromyeloid progenitors (EMPs) in the yolk sac (42) during primitive 
haematopoiesis. This was shown by fate mapping using a transgenic line where 
progenitor cells that express runt-related transcription factor 1 (RUNX1) 
express YFP after tamoxifen-induced Cre recombination (42). Injection of 4-
hydroxytamoxifen (4-OHT) into pregnant females prior to definitive 
haematopoiesis (at E7.5) allowed for specific labelling of yolk sac derived EMPs 
that were traced to the developing brain (42). This migratory process is 
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circulation-dependant, as sodium-calcium exchanger knockout mice (Ncx‐1-/-) 
that develop without a functioning blood circulation lack CNS microglia (55) 
despite undergoing normal haematopoiesis (42). EMPs commit to a microglia 
fate by massive changes in gene and protein expression, firstly by differentiating 
into CD45+c-KitloCX3CR1- precursors and then maturing into CD45+c-Kit-
CX3CR1+ yolk sac macrophages (51). Once in the CNS, these cells downregulate 
Timd4 and Cd206 and upregulate microglial signature genes Sall1 and Sall3	(56). 
Microglia specification is also dependent upon interferon regulatory factor 8 
(IRF-8), working in a heterodimeric partnership with transcription factor PU.1 
(51). Furthermore, RNA-seq analysis revealed precise coordination of gene 
expression that directs differentiation of early progenitors (expressing Mcm5, 
Dab2, Lyz2 and Pf4) into post-natal microglia (upregulating Csf1R and Cxcr2) 
and then finally into mature microglia (expressing Cd14 and Mafb) (57).  
Furthermore, microglial maturation in the CNS is dependent on factors 
produced by other CNS-resident cell types. For example, an in	vitro co-culture 
study of astrocytes with microglia show that after one week microglia elongate 
and become ramified, suggestive of maturation, and astrocyte conditioned 
media alone can also induce this (58.59). Moreover, ex	vivo experiments have 
shown that astrocyte-derived factors including TGF-B2, CSF1 and cholesterol 
can also promote the ramification and survival of microglia (60). Co-culture 
studies of induced pluripotent stem cell (iPSC) derived neurons and primitive 
macrophages lead to dramatic morphological changes in the macrophages 
similar to ramified microglia (58), although this did not take place with 
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neuronal conditioned media alone, suggesting direct contact between neurons 
and primitive macrophages may be needed to induce maturation.   
Yolk sac-derived microglia can persist throughout adulthood (42,	59,	60), 
although there is a possibility that some microglia may be replaced by 
haematopoietic stem cells (HSCs). This is because adult microglia in the 
zebrafish originate from the ventral wall of the dorsal aorta (VDA), a source of 
definitive haematopoiesis (59), although it is unclear whether this reflects 
differences in developmental pathways between species. However, recent 
experimental evidence using a Vav-1+Cre:Dicer mouse model, in which 
definitive haematopoiesis is prevented, showed a 40% reduction in IBA-1+ cells 
in the CNS compared to WT littermates, suggesting a second wave of microglial 
infiltration to the developing CNS originating HSCs (61). However, in light of 
recent evidence demonstrating a transient population of monocyte-derived 
macrophages entering the CNS during development (62) and a lack of 
microglial-specific markers used in the Vav-1Cre:Dicer experiments, it cannot 
be ruled out that this model is only preventing the migration of a transient 
macrophage population. Rapid and dramatic increases in microglia numbers are 
observed in the CNS shortly after birth in the mouse (50,	61), although whether 
this a second wave of microglia or a peripheral cell contribution is debated. 
Indeed, in a PU.1 knockout mouse model (lacking embryonic microglia), bone-
marrow transplants from wild type mice can lead to a fully populated microglial 
presence in the CNS (63) however it is unclear the extent to which blood-
derived monocytes contribute to the stable microglial population in the CNS 




In the first two weeks of life after birth, microglial numbers increase, which is 
then followed by a decrease to a steady homeostatic level via apoptosis and 
reduced proliferation (50,	64,	65). Under homeostatic conditions, yolk-sac 
derived microglia were historically considered to be long-lived cells with low 
turnover, however it has recently been shown that microglia numbers in the 
mouse brain are dynamically regulated by  apoptosis and proliferation, with 
around 1.38% of microglia estimated to be proliferating (as shown by BrdU 
incorporation) and 1.23% of microglia dying every 24 hours (66). Therefore, it 
is estimated that an entire microglial population in the mouse CNS can turn over 
in 96 days.  In the human brain, slightly higher rates of proliferation were 
observed (Ki67+ IBA-1+ cells), but rates of death are unknown. Dynamic 
regulation of the microglia population in the adult mouse brain has also been 
observed by repopulation from CNS-resident cells following global depletion of 
microglia (66‐69). As these studies involved adult mice rather than neonates, 
this reveals that repopulation of microglia differs from the original seeding 
taking place during development. There are currently 2 proposed models to 
explain how microglia repopulation in the adult CNS takes place. The first study 
using a Cx3cr1-CreERT2;iDTR mouse model ablated a minimum of 80% of 
microglia in the cortex, cerebellum, and spinal cord by 3 days post-diphtheria 
toxin (DT) administration (68). A rapid microglial repopulation event was 
observed at 7 days post-DT, mediated by self-renewing proliferating microglia 
(expressing Nestin), with numbers returning to control levels 1 week later (68). 
The second model, where >99% of microglia were depleted using a CSF1R 
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inhibitor, observed repopulation from a CX3CR1 negative CNS-resident cell (69). 
Furthermore, BrdU labelling showed that 70% of labelled cells were Nestin+ but 
negative for microglia markers such as IBA-1. When repopulation was complete, 
almost all BrdU labelled cells were positive for microglial markers, leading to 
the conclusion that the Nestin+ cells differentiated into microglia (69).  These 
repopulating cells heterogeneously expressed a range of markers for 
hematopoietic and neural stem cells including Nestin, c-kit, and CD34, as well as 
lectin-IB4, CD45, and Ki67 (69). The repopulated microglia also have similar 
inflammatory gene expression and functional responses to lipopolysaccharide 
compared to pre-depletion microglia (69). However, the identity and origin of 
these progenitor cells remains unclear. Definitive lineage tracing and RNA-
sequencing of these Nestin+ cells in all depletion studies would be beneficial in 
uncovering their identity and role in the CNS.  Indeed, lineage tracing of 
repopulating microglia in two depletion/repopulation studies have both 
concluded that residual microglia are the sole source of repopulation after 
depletion, with no evidence for a Nestin+ cell origin (68,	70), however whether 
this is the case for all depletion studies remains to be determined. Differences in 
repopulation outcomes in all depletion studies may reflect how different 
depletion methods and the extent of depletion (>99% (69) compared to 80% 
(68) for example),  impact other neural cell types, as only the DTR-driven 
depletion lead to a robust pro-CNS inflammatory response and astrogliosis (68) 
which may also impact how repopulation takes place. Although there is 
uncertainty as to the role of Nestin in microglia repopulation, be it re-expression 
by residual microglia (68,	70) or progenitor cells capable of differentiating into 
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microglia (69), cells expressing Nestin are nonetheless integral to the rapid 







Microglia can respond to a multitude of factors in their microenvironment, 
interacting with other cell types and responding to secreted products (such as 
cytokines). They also survey their environment for signs of injury by the 
detection of damage-associated molecular patterns (DAMPS) released by 
damaged and dying cells and by identifying signs of infection by the detection of 
pathogen-associated molecular patterns (PAMPS) (71). As a result, microglia 
can adopt differential functional responses associated with changes in 
particular marker expression, known to indicate different ‘activation’ 
phenotypes. Furthermore, their phenotype can also reflect different functions, 
particularly relevant in models of CNS injury and regeneration. Insight into how 
their phenotypes and functions are regulated may provide greater insight into 
the possibility of targeting microglia therapeutically in order to promote CNS 
repair.  
Historically, microglia were characterised broadly into two polarising 
categories, with ‘M1’ classifying microglia activated to a pro-inflammatory state, 
and ‘M2’ describing anti-inflammatory/ tissue reparative microglia. However, 
this terminology originated from activating peripherally derived macrophages 
in	vitro with either interferon gamma (IFN-γ; M1) or interleukin 4 (IL-4; M2), 
and later, by treatment with granulocyte macrophage colony stimulating factor 
(GM-CSF; M1) or macrophage colony stimulating factor (M-CSF; M2) (72). It was 
then recognised that macrophages responded differently to other stimuli, and 
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so additional categories including M2a, M2b and M2c were devised. The ‘M1’-
‘M2’ paradigm was further scrutinised following profiling of 299 human-derived 
macrophage transcriptomes subjected to 29 different stimuli in	vitro, showing 
by co-regulation and Pearson correlation analysis that there were large 
diversities in transcript expression profiles that did not fit into the classic ‘M1’ 
or ‘M2’ profiles (73). Additionally, genome-wide expression profiling of 
microglia from different mouse models of CNS disease including amyotrophic 
lateral sclerosis (ALS) (74), EAE (75) and traumatic brain injury (TBI) (76) 
failed to show evidence that microglia fall simply into an M1 or M2 category. 
Therefore there is substantial evidence for this paradigm oversimplifying and 
underestimating the activation potential of microglia, and in order to avoid 
assumptions of gene expression or function that may impede experimental 
reproducibility, Murray at al., (77) proposed to define macrophage activation by 
stimuli used, experimental conditions and a combination of markers.  
Although in	vitro stimulation of macrophages may not recapitulate the full 
complexity of the	in	vivo environment, it has still given researchers useful 
insight into gene expression profiles and biochemical/functional responses 
associated with different microglial activation states (78). For example, in	vitro 
activation using combinations of potent inflammatory mediators including 
interferon gamma (IFN-γ) and bacterial peptide lipopolysaccharide (LPS), IFN-γ 
and Fc receptor (FcγR) stimulation, or IL-4 treatment alone produce unique 
gene, transcript and protein expression patterns, such that only macrophages 
exposed to IFN-γ express pro-inflammatory associated enzyme inducible nitric 
oxide synthase (iNOS), whilst only IL-4-treated macrophages express anti-
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inflammatory marker arginase-1 (Arg-1) (78). It is important to note that 
exposure of macrophages to different inflammatory environments not only 
induces differential marker expression, but also distinct functions and 
behaviours. This was first shown by identifying that microglia exposed to 
different inflammatory mediators in	vitro could influence distinct neural 
progenitor responses (79). Co-culturing LPS-treated microglia with neural 
progenitor cells (NPCs) or OPCs blocked progenitor cell differentiation via 
microglial secretion of pro inflammatory TNF-α (79). Although both IFN-γ and 
IL-4 co-cultures promoted NPC differentiation into oligodendrocytes, the effects 
of IL-4 on oligodendrogenesis were much more pronounced, through secretion 
of high levels of IGF-1 (79). Previous studies from our lab have found that 
microglia treated with IFN-γ and LPS  express  iNOS, co-stimulation molecule 
CD86, and Fc receptor CD16/32, associated with in	vitro induction of OPC 
proliferation and migration (8). Conversely, only treatment with IL-13 or IL-10 
increased expression of Arg-1, mannose receptor and IL1Ra, and conditioned 
media from these cultures enhances OPC survival under death-inducing 
conditions and OPC differentiation into mature oligodendrocytes (8). Although 
these experiments were carried out under artificial environments, they have 
helped to reveal the importance of microglia-derived factors in regulating 





The diversity in microglial activation can significantly impact regeneration in 
the CNS. For example, in a spinal cord injury model using electromechanical 
displacement where axon regeneration is poor, gene expression profiles 
previously associated with macrophage activation changed dynamically over 
time after injury (80). Early time points were associated with increased 
expression of pro-inflammatory mediators iNOS, CD16/32, CD86, IFN-γ, as well 
as mannose receptor and Arg-1, whereas expression of mannose receptor and 
Arg-1 decreased at later time points, pro-inflammatory mRNA levels persisted. 
This suggested that an unresolved, chronic pro-inflammatory microglial 
phenotype in CNS lesions may be associated with poor axonal regeneration. 
Injection of IL-4 treated macrophages did not rescue this effect, as once injected 
these cells changed their phenotype to mirror the inflammatory environment in 
the lesion. However, direct delivery of IL-4 into the CNS was able to overcome 
this, and induce a pro-regenerative Arg-1+ macrophage phenotype (81,	82), as 
well as markedly improving functional outcome and reducing tissue damage 
compared to non-IL-4 treated lesions with chronic pro-inflammatory microglia 
(82). IL-4 injection also had a pro-regenerative effect in the EAE model, where it 
increased oligodendrogenesis in the spinal cord, suggesting a role for 
microglia/macrophages in remyelination. The first evidence of microglial/ 
macrophage involvement in remyelination came from using LPC to induce a 
focal demyelinating lesion in the mouse spinal cord, and showing that depletion 
of macrophages early after injury using clodronate liposomes results in a 
significant delay in remyelination (83). This study therefore showed the 
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importance of microglia in promoting remyelination after injury. The pro-
regenerative role of microglia was later associated with many functions 
including phagocytosis of myelin debris, clearance of which is vital for 
remyelination to take place (84,	85) and recruitment of OPCs  to lesions (86). 
Previous work from our lab subsequently showed that dynamic temporal 
regulation of microglia/macrophage activation controls OPC responses during 
remyelination (8). Using LPC to induce a focal demyelinating lesion in the mouse 
corpus callosum, microglia/macrophage activation was investigated over time 
during remyelination using markers associated with macrophages in 
regeneration of other tissues (80,	87‐89). Immunostaining revealed that a 
iNOS+CD16/32+TNF-α+ microglia/macrophage population was present at 3 
days post lesion, which by 10 days post lesion switched to an Arg-1+IGF-
1+mannose receptor+ population. Depletion of the pro-inflammatory iNOS+ 
population using gadolinium chloride (GdCl3) (inhibitor of calcium signalling, 
previously used to deplete pro-inflammatory macrophages in	vivo; (90)) 
reduced OPC proliferation, whereas specific depletion of the mannose 
receptor+/Arg-1+ population using mannosylated-clodronate liposomes 
reduced OPC differentiation into mature oligodendrocytes and impaired 
remyelination (8). Additionally parabiotic studies where the circulation of a 
young mouse was connected to an old lesioned mouse caused  enhanced 
remyelination in the latter (91).  Recruitment of young macrophages to the 
lesion was associated with an increase in Arg-1+ and mannose-receptor+ cells, 
but not iNOS+ or CD16/32+ microglia/macrophages, therefore associating the 
increased Arg-1+ population with improved remyelination (8,	91). Interestingly, 
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lineage tracing demonstrated that only a small proportion of the Arg-1+ 
macrophages were derived from the young mouse, showing that old microglia/ 
macrophages have the capacity to adopt the regenerative phenotype when 
exposed to the young macrophages (8).  Furthermore, another study blocking 
secreted TNF-α in the cuprizone model improved phagocytosis of myelin debris, 
promoted early remyelination, and prevented the disease-associated decline in 
motor function (92). Altogether, these studies have demonstrated how dynamic 
regulation of microglia/macrophages can be dependent on the CNS 
microenvironment, resulting in adoption of activation phenotypes that either 
impede or promote regeneration. A key commonality between these studies is 
that the temporal regulation of microglia/macrophage activation, i.e., a turning 
off of “pro-inflammatory” responses and switch to “pro-regenerative” function, 









Diagram	2. Microglial activation regulates OPC responses and remyelination. Pro-
inflammatory microglia, identified by their expression of pro-inflammatory markers 
such as iNOS and TNF-α, drive the proliferation of OPCs, but for efficient remyelination 
to take place, microglia must transition to an anti-inflammatory/ pro-reparative 
phenotype that express Arg-1/ mannose receptor (CD206) and secrete IGF-1 and TGF-







Destruction of myelin in MS is associated with microglia and macrophages (93,	
94), both of which are thought to be important in the pathogenesis of the 
disease. Interestingly, increased densities of microglia and macrophages have 
also been associated with remyelination of MS lesions in some studies (8,	95), 
demonstrating their regenerative potential in the CNS, and highlighting their 
dual roles in degeneration and regeneration. Microglia play important roles in 
inflammation and immune responses, expressing major histocompatibility 
complexes (MHC) I and II, and complement receptors CR1, 2 and 4  to potentiate 
immune responses, and secreting potent inflammatory factors including TNF-α, 
interleukin (IL)-1 and IL-10 (96). Microglial activation in MS is complex; 
experimentally, microglia can drive inflammation and damage oligodendrocytes 
and myelin sheaths (97), yet can also resolve inflammation and promote tissue 
repair by their secretion of anti-inflammatory and tissue reparative factors (7,	
8). Activated microglia and macrophages in active MS lesions have been shown 
to be a major source of oxidative species release that most likely contributes to 
myelin pathology (98) and have also been shown to localise near damaged 
axons, suggesting a role in neurodegeneration (99). Lesions that fail to 
remyelinate in MS are associated with an abundance of iNOS+ pro-inflammatory 
microglia, and “active” lesions with high remyelination potential are associated 
with mannose receptor+ pro-regenerative microglia (8). Furthermore, it is 
thought that chronic pro-inflammatory activation of microglia may be at least 
part responsible for driving the pathogenesis of MS. Microglia therefore may 
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hold important insight into how to not only resolve inflammation, but also 
promote remyelination in diseases like MS.  
Microglia and macrophages represent the majority of immune cells in active MS 
lesions (100). Recent advances have allowed for the differentiation of microglia 
and monocyte derived macrophages (MDMs) by the identification of microglial-
specific markers including TMEM119 and P2RY12 (101‐103). Distinguishing 
between these two macrophage populations enables greater insight into the 
differing roles both populations play in diseases like MS. Strong evidence for the 
distinct roles of microglia and MDMs in such diseases came from experiments 
using the EAE model. Using Cx3cr1GFP/+ and Ccr2RFP/+ mice to distinguish 
microglia (GFP+) from MDMs (RFP+), the authors were able to show that MDMs 
were closely associated with demyelinating axons, and may initiate 
demyelination (75). Conversely, microglia were associated with the clearance of 
debris, and displayed much less of an activated morphology. Furthermore, Ccr2 
knockout mice (which inhibits MDM migration and therefore infiltration of the 
CNS) displayed a significant reduction in demyelinated white matter areas 
compared to controls, supporting the role of MDMs in driving demyelination. 
Gene expression profiling of microglia and MDMs revealed distinct 
inflammatory signatures in both populations, such that MDMs displayed a much 
more dramatic increase in inflammation and phagocytosis associated gene 
expression at the onset of EAE, whereas microglia downregulated many genes 
including those associated with cellular metabolism (75), highlighting the 
pathogenic role of MDMs in EAE. It is important to note that not all MDMs 
express CCR2 (104) and therefore other MDMs may have underappreciated 
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roles in this study.   Furthermore, the early response of MDMs compared to 
microglia may reflect the peripheral route of adjuvant/myelin protein 
administration.  Indeed, human TMEM119+ IBA-1+ microglia rather than MDMs 
(TMEM119-IBA-1+) have been shown to be present early during lesion 
formation in MS, dominating new active lesions and the site of expansion in 
chronic lesions (105‐107), and therefore may play a more active role in MS 
compared to what is observed in experimental models. 
Antigen presentation from microglia and perivascular macrophages enables 
communication with the adaptive immune system, particularly T-cells. Although 
perivascular macrophages constitutively express MHC Class II proteins (108), 
expression is further upregulated in these cells in MS lesions. Human microglia 
within the CNS parenchyma express much lower levels of MHC class II (109), 
although they can upregulate this expression after damage or infection (110). 
Although this suggested that both microglia and macrophages are capable of 
antigen presentation to T-cells to drive autoimmunity, recent evidence using 
microglial-specific (Cx3cr1 promotor-driven Cre) knockout of MHCII proteins 
(which did not affect peripheral myeloid cells) showed that disease progression 
and severity of EAE was unaltered (111), suggesting antigen presentation is 
peripheral myeloid cell-driven.  This was further supported by monocyte 
ablation which significantly ablated disease progression, although monocyte-
specific MHCII knockout studies were not carried out. Susceptibility to MS has 
been linked with particular MHC class II protein variants, e.g. HLA-DRB1 (112‐
114).  It is unclear however if microglial activation, or adaptive immune system 
dysregulation drives the initial pathology in MS. Experimental evidence in EAE 
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has shown that microglia become activated before the onset of lesion formation, 
and depletion of microglia in EAE attenuates disease progression (115,	116), 
which would therefore suggest that microglia can indeed promote disease 
progression. However, there was no discrimination between microglia and 
MDMs in these studies, so it is unclear to the extent that microglia and MDMs 
play in the pathogenesis of the disease.   
 
1.7.2.	Microglial	Phenotypes	in	MS	and	disease	models	of	MS	
Given the importance of microglial activation states in remyelination, it has 
been postulated that dysregulation of microglial/ macrophage activation may 
contribute to the failure of remyelination in MS. Microglia and macrophages in 
early active lesions are associated with a pro-inflammatory phenotype, 
particularly associated with phagocytosis (CD68), antigen presentation (MHC I 
and II, CD86) and reactive oxygen species production (p22phox), but later 
active lesions are associated with anti-inflammatory and tissue reparative 
markers like CD206 and CD163 (106), which may be a sign of lesion repair. 
Indeed, chronic inactive lesions associated with poor remyelination potential 
are associated an abundance of iNOS+ macrophages whereas mannose 
receptor+ macrophages are associated with acute lesions with high 
remyelination potential (8,	117), suggesting that a phenotypic switch in 
microglial activation may be necessary for lesion repair. Furthermore, oxidative 
burst from pro-inflammatory microglia and macrophages are thought to be the 
major source of reactive oxygen species in MS (118). Lipid and DNA oxidation 
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levels correlate with increases in oxidative injury to oligodendrocytes and 
neurons, associated with active demyelination and neurodegeneration (119), 
indicating how pro-inflammatory microglia and macrophages can cause 
significant damage during chronic inflammation. Interestingly, a population of 
macrophages with an “intermediate” phenotype, characterized by expression of 
CD86, CCL22 and costimulatory molecule CD40, and negative for mannose 
receptor, are present in “pre-active” normal appearing white matter (NAWM) 
and remyelinating lesions, suggestive of a population of macrophages caught 
mid-switch  (120). However, another intermediate macrophage population, this 
time identified by the expression of CD40 and mannose receptor, is associated 
with chronic inactive lesions that fail to remyelinate (117) suggestive in this 
case of a pathological block in macrophage phenotypic switching. The balance 
between macrophage activation states is predictive of disease severity in EAE.  
An abundance of iNOS+ macrophages is associated with a significantly higher 
risk of relapsing EAE, and equal numbers of iNOS+ and Arg-1+ macrophage 
populations predicts a milder disease outcome (121). Additionally, high 
numbers of Arg-1+ microglia/ macrophages are associated with attenuation of 
inflammation and decreased disease severity (122). Work from Mikita et al., 
(121)) demonstrated the importance of Arg-1+ macrophages in the recovery of 
EAE suggesting that promoting their activation may represent a novel 
therapeutic target for MS. Whereas increased iNOS expression in circulating 
monocytes and suppression of Arg-1+ macrophages and microglia predicted 
increased relapse occurrences, milder pathologies were characterized by low 
numbers of activated iNOS+ monocytes in the brain stem. Furthermore, 
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administration of IL-13- and IL-4-treated monocytes decreased disease severity 
significantly, accompanied by increased Arg-1 expression in the brain stem. 
These studies suggested that promoting activation of macrophages associated 








Macrophages are able to rapidly and dynamically respond to stimuli in their 
microenvironment, and as such are known for their plasticity in responses and 
functions. The concept of “macrophage plasticity” suggests that they are able to 
adjust their activation and function, or even revert to a homeostatic ‘surveying’ 
state in response to changes in their microenvironment. This is an important 
concept as it suggests that it may be possible to therapeutically target the ability 
of microglia/ macrophages to switch from pro-inflammatory (and damaging if 
chronically active) to pro-regenerative activation states. However, it remains to 
be determined if macrophages have the potential to undergo an in	situ switch, 
changing their genetic, metabolic and functional states in response to different 
stimuli.  
There are many in	vitro studies aimed at reversing or switching microglial 
phenotypes once polarised, identified by observing changes in gene and protein 
expression. However, LPS treatment of microglia followed by treatment with IL-
4 could not reverse the production of TNF-α or promote the production of IGF-1 
(79). Whether this shows that pro-inflammatory activation commits the cells to 
an irreversible fate or reflects the potency of LPS as an irreversible 
inflammatory stimuli remains uncertain. However, other similar experiments 
treating microglia with LPS followed by IL-4 have shown a significant decrease 
in the mRNA expression of pro-inflammatory genes iNOS, Cox-2 and CD86, with 
increased expression of mannose receptor and Arg-1 surpassing expression 
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levels that were observed with IL-4 treatment alone (123). Contradictions in 
experimental outcomes in these studies may be due to differences in culture 
conditions, treatment exposure times and experimental end points. Polarising 
anti-inflammatory microglia to a pro-inflammatory phenotype seems to be 
easier to achieve, as although IL-4 treated microglia do not produce IL-10, 
addition of LPS induces a modest production of microglial IL-10, suggesting that 
plasticity of polarised microglia is possible (78). Furthermore, IL-4-induced IGF- 
1 production was blocked by LPS co-treatment (79). However, it is unclear how 
biologically relevant in	vitro microglia and macrophage studies are, and 
therefore suitable ex	vivo and in	vivo models are warranted.  
Indeed, there is in	vivo evidence for changes in macrophage activation following 
CNS injury. In a model of rodent contusion-induced spinal cord injury, distinct 
populations of macrophages are recruited to the lesion site through different 
routes such that Ly6ChiCX3CR1lo macrophages associated with expression of IL-
1β, TNF-α, and IL-12 are recruited through the leptomeninges, and 
Ly6CloCX3CR1-GFPhi macrophages expressing mannose receptor, IL-10 and 
TGF-β are recruited via the choroid plexus (80,	124). This research gave a new 
perspective on microglial/ macrophage plasticity by showing how the choroid 
plexus may prime macrophages to become pro-regenerative prior to exposure 
of damage at the lesion site, a previously unidentified mechanism regulating 
macrophage diversity. 
Cross-talk between macrophage signal transduction pathways involved in both 
the initiation and resolution of inflammation during remyelination results in 
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tightly regulated responses. For example, msh homeobox 3 (MSX3) promotes 
pro-regenerative responses in microglia that lead to oligodendrocyte survival in	
vitro and suppression of EAE in	vivo, potentially through its ability to suppress 
pro-inflammatory pathway activation (125). MSX3 leads to activation of PPARγ 
and STAT6, both of which are able to inhibit pro-inflammatory pathways 
including NFκB (126,	127). Transcriptional profiling of LPS-treated microglia in	
vitro showed that 72 out of 465 NFκB target genes analysed were significantly 
repressed or induced (128). Moreover, expression of CD40, a costimulatory 
molecule associated with autoimmunity and implicated in MS, is upregulated in 
microglia and macrophages following LPS treatment via activation of NFκB 
(129). Its tight autoregulation ensures rapid activation that is controlled and 
resolved efficiently; however dysregulation can lead to a prolonged 
inflammatory response and neurodegeneration. Mutations in genes associated 
with inhibition (130) or constitutive activation of NFκB (131) have been found 
in peripheral blood mononuclear cells (PBMCs) of patients with MS (132). 
Furthermore, another study showed by immunostaining post mortem tissue 
from MS patients that strong NFκB activity was localized to microglia and 
macrophages near lesions (133), suggesting that a lack of regulation of NFκB 
may contribute to the inflammation and pathology of the disease. Therefore, a 
switch in macrophage phenotype and functions may be achieved by blocking the 
activation of inflammatory pathways such as those mediated by NFκB, leading 





Endogenous regulators of inflammation may also provide clues as to how 
microglia and macrophage activation are regulated during CNS injury and 
repair. One example is of PPARγ; when activated, it translocates to the nucleus 
and is able to bind to NFκB-specific binding sites, preventing NFκB activation 
and the transcription of pro-inflammatory mediators in a process called trans-
repression (134,	135).  As such, it has long represented a promising 
experimental candidate to suppress inflammation and promote repair. 
Administration of a PPARγ agonist in	vivo has previously been shown to 
promote functional recovery in a rodent spinal cord injury (SCI) model (136) 
and neuroprotection when administered before EAE induction (137), although 
it is uncertain whether PPARγ agonists can promote recovery in these models 
through other cell types, as PPARγ receptors are ubiquitously expressed. 
However, PPARγ expression is upregulated in IL-4 treated microglia in	vitro 
(135), and is associated with anti-inflammatory/ pro-regenerative microglia. 
Indeed, In	vitro activation with specific PPARγ agonists can decrease pro-
inflammatory and increase anti-inflammatory marker expression in 
macrophages infected with the parasite t.Cruzi, a parasitic protozoan that 
causes a potent pro-inflammatory response in macrophages (138). PPARγ 
activation also promotes the transcription of anti-inflammatory molecules such 
as IL-10 (134) and has therefore been suggested to be a potential activation 
switch regulator for microglia and macrophages.  
Another example is the neuropeptide Substance P, a member of the tachykinin 
family most characterised in the perception of pain and release from sensory 
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neurons. Substance P has also been shown to promote activation or infiltration 
of tissue-reparative macrophages in	vivo, and its receptor Neurokinin 1 is 
upregulated in IL-4-treated macrophages in	vitro (139). In a model of spinal 
cord contusion, Substance P administration at the time of injury induction 
significantly decreased iNOS, IL-6, and TNF-α mRNA expression whilst 
increasing IL-10 and Arg-1 expression, as well as being associated with 
increased mannose receptor+ macrophages, conserved myelin sheaths and 
functional recovery (140).  
17β-Estradiol, the main estrogen produce by the pre-menopausal ovary can 
prevent NFκB activation in macrophages by directly disrupting the 
microtubules important for the translocation of NFκB to the nucleus, thereby 
preventing transcription of NFκB-dependant pro-inflammatory mediators 
(141), and can additionally promote PPARγ activation (142). Administration of 
17β-Estradiol in EAE decreases inflammatory cell infiltration, delays the onset 
of symptoms and prevents deterioration of neurological function (143). This is 
associated with decreased protein levels of pro-inflammatory mediators 
including IL-1β, TNF- α, IL-17, Rho kinase II, and increased IL-4 (143). 
Furthermore, in	vitro treatment of macrophages with 17β-Estradiol significantly 
decreases LPS-induced IL-1α, IL-6, and TNF- α protein expression (144).  
Lastly, inhibition of an upstream activator of the NFκB pathway, Rho kinase, 
with the Rho kinase inhibitor Fasudil modulates microglial activation, reduces 
microglial infiltration to the spinal cord and improves functional outcome in the 
SOD1 mutant mouse model of ALS (145). In	vitro treatment of microglial 
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cultures with Fasudil also decreases LPS-induced protein expression of TNF-α, 
IL-6, and inflammatory chemokines CCL3, CCL5 and CXCL1.  
Although our own lab demonstrated changes in the activation and function of 
microglia/ macrophages during efficient remyelination, a direct in	situ switch in 
the same cells remains unproven. Evidence suggests that either microglia can 
adopt polarising phenotypes, or distinct populations are regulated in response 
to the environment. Uncovering how microglial phenotypes are regulated 
during remyelination will be important in order to understand how to prevent 
chronic inflammatory microglial activation. Furthermore, this knowledge will 
give a greater insight into finding ways to specifically promote a microglial pro- 
regenerative phenotype that may represent a novel therapeutic method in 
promoting remyelination.  
 
1.8.3.	Microglia	Heterogeneity	
Not only can microglia adopt different genetic and functional identities in 
response to differing stimuli, it has been shown in recent years that CNS 
regional heterogeneity exists in homeostatic conditions. The first evidence for 
this was almost 30 years ago by immunohistochemical staining of microglia in 
different CNS regions (146). Immunostaining of microglia marker F4/80 
revealed significant differences in microglia density throughout the brain; grey 
matter areas in particular had greater overall densities of microglia compared 
to white matter areas. Furthermore, microglia represented 5% of all cells in the 
cortex compared to representing 12% of the total cell population in the 
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Substantia Nigra (SN). Regional differences in microglial density did not 
necessarily correlate with levels of developmental cell death in each region, and 
therefore regional differences in microglial densities is not as a result of 
microglial activity during development. Additionally, morphological 
heterogeneity was also observed between CNS regions, ranging from round and 
compact to highly branched. Taken together, this was the first evidence to 
suggest that microglial heterogeneity may be a result of microenvironmental 
heterogeneity.  
Since then, other studies have aimed to uncover factors that underpin microglial 
heterogeneity. Transcriptional profiling of adult microglia from distinct brain 
regions (cerebellum, hippocampus, striatum and cerebral cortex) revealed 
interesting regional differences in gene expression profiles (147). Principle 
component analysis showed particular differences in pathways involved in 
respiration and metabolism including glycolysis, TCA cycle and ATP synthesis, 
with cerebellar and hippocampal microglia being the most energy-demanding 
(147,	148). Furthermore, comparison of each regional microglial group with 
LPS-induced activated microglia gene expression data uncovered similar 
upregulation of genes associated with microglial activation in cerebellar 
microglia, suggesting an increased state of ‘alertness’ in these cells. 
Interestingly, transcriptomic analysis of microglia from adulthood to early and 
late ageing showed regional-dependant changes in gene expression profiles in 
response to ageing. In particular, cerebellar microglia showed increases in 
genes associated with activation (Sirpb1a,	Trem3,	Trem1,	Cd300), as well as 
showing greater transcriptomic diversity from other regional microglia over 
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time. Conversely, hippocampal microglia displayed a decrease in distinction 
from other microglial groups with ageing, demonstrating how ageing impacts 
microglia differently in a region-dependant manner. Loss of microglial 
homeostatic identity has been previously associated with activation in MS (106), 
and ageing revealed a loss of homeostatic gene expression (Tmem119,	P2ry12,	
Fcrls) in microglia from all regions, but particularly in cerebellar microglia 
(147). This may help to understand why microglia in ageing and in diseases like 
MS are associated with dysregulated pro-inflammatory activation that fails to 
resolve.   
Regional heterogeneity of microglia occurs even in structures with close 
proximity. For example, analysis of microglia from 4 regions of the basal ganglia 
revealed marked differences in density, morphology, activity and 
transcriptomics (149). Interestingly, the Substantia Nigra reticulata (SNr) had 
the greatest density of microglia (723/mm2), up to 3 times the density of other 
areas such as the Ventral Tegmental Area (VTA; 262/mm2), as well as having 
the most metabolically active microglia (indicated by numbers of lysosomes per 
microglia). Conversely, despite having the lowest microglia density, the VTA 
microglia had the highest transcriptomic diversity compared the other nuclei, 
although microglia-specific genes (Tmem119,	Csf1r,	Fcrls,	P2ry12	etc) were 
highly conserved throughout all microglia populations. Depletion of microglia 
using a CSF1R inhibitor or via genetic ablation with Cx3cr1-DTR mice revealed 
that repopulation lead to the same regional differences in density, morphology 




Important questions have arisen from these important studies. A previous study 
showed that taking microglia out of the brain into an in	vitro environment lead 
to vast changes in gene expression, and therefore environmental factors shape 
microglia identity (150). However, it is still unclear if established microglia 
transplanted to a distinct brain region change in response to their new 
environment. Furthermore, although comparisons of brain and spinal cord 
microglia after LPS-induced inflammation revealed differences in magnitude of 
microglial responses (151), a closer examination of regional differences in 
microglial responses to inflammatory stimuli may help to understand why 
pathological responses and ageing of microglia occur in a region-dependant 
manner.  
Taken together, there is vast evidence for the involvement of microglia not only 
in the initiation and progression of CNS damage and disease, but also in the 
resolution of inflammation and promotion of tissue repair, and the regional 
heterogeneity of microglial activation in these processes. Understanding how 
microglia become activated during efficient remyelination will uncover ways to 
harness their regenerative properties in chronic inflammatory and 






Given that a transition in microglia activation from a pro-inflammatory to pro-
regenerative phenotype is critical for efficient remyelination, and that persistent 
pro-inflammatory microglial activation is associated with remyelination in 
diseases like MS, it is imperative to understand the mechanisms that underpin 
microglial activation and phenotype transitioning during efficient 
remyelination. Harnessing the regenerative properties of microglia may 
represent a novel therapeutic target not only for modulating inflammation, but 
also in promoting remyelination.  
Although uncertain, in	vitro evidence suggests that pharmacological 
manipulation can ‘switch’ polarised microglia from one phenotype to another 
(80,	152), therefore the initial hypothesis of this PhD was that microglia undergo 
a direct phenotypic switch during efficient remyelination.  
The aims of this thesis are: 
1. To investigate the cellular and molecular mechanisms that drive 
microglial activation and phenotype transitioning during efficient 
remyelination 
2. To identify immunomodulatory compounds capable of promoting pro-







All experiments were performed under UK Home Office project licences issued 
under the Animals (Scientific Procedures) Act (1986) and the EU Directive 
2010/63 in accordance with the ARRIVE guidelines. Animals were housed at 6 
animals per cage in a 12 hour light/dark cycle with unrestricted access to food 
and water. Wild type CD1 mice were used for organotypic cerebellar slice 
cultures and C57Bl6/J mice used for in	vivo	demyelination experiments. To 
track monocyte infiltration into in	vivo lesions, we used heterozygous Ccr2 
knockin reporter mice (B6;129(Cg)-Ccr2tm2.1lfc/J). For lineage tracing, Ai9 
(B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) were crossed with C57Bl6-
Tg(Nes-CreERT2)KEisc/J to induce tdTomato expression in Nestin+ cells, or 
crossed to Cx3cr1-CreER to induce tdTomato expression in microglia. 
Recombination was induced by overnight treatment with 1 µm 4-hydroxy-
tamoxifen (4OHT; Sigma-Aldrich), then washed thrice immediately followed by 
an additional 3 media changes over the course of the subsequent week prior to 
demyelination. Sprague-Dawley rats were used for primary microglial cultures. 
All animals were purchased from Jackson Laboratories. 
	
2.2.	Genotyping		
Genomic DNA was extracted from ear tissue using the Wizard SV genomic 
purification system (Promega) according to the manufacturer’s instructions. 
Mice were genotyped using PCR strategies as previously described (153). 
57 
 
Briefly, MacGreen (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J) mice were genotyped 
using primers 79 (ATCATGGCCGACAAGCAGAAGAAC) and 80 
(GTACAGCTCGTCCATGCCGAGAGT). NestinCreTdTomato ((B6;129S6-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) mice were genotyped using primers 1084 
(GCGGTCTGGCAGTAAAAACTATC), 1085 (GTGAAACAGCATTGCTGTCACTT), 





Microglia were derived from mixed glial cultures of P0-P3 Sprague-Dawley rats 
by differential adhesion, as previously described (8). Cells were plated on poly-
D-lysine-coated 16 well glass chamber slides (Lab-TEK) at 5 x 104 cells per well 
in Dulbecco’s Modified Essential Media (DMEM) containing 4.5 g/L glucose, l-
glutamine, pyruvate, 10% fetal calf serum (Gibco 26050088; vol/vol) and 1% 
penicillin/streptomycin (Life Technologies 15140122; vol/vol). Microglia were 




Treatment included LPC (L4129; 0.5 mg/ml in PBS) or interferon-gamma from 
mouse (I4777; 20 ng/ml in PBS) and lipopolysaccharide (LPS) (0127:B8; 100 
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ng/ml in PBS) (all from Sigma-Aldrich) from 2-30 hours prior to fixation with 
4% paraformaldehyde (in PBS) for 10 minutes (P6148; Sigma).  
 
2.3.3.	Immunostaining		
Cells were blocked for 1 hour (5% BSA, 0.03% Triton-X in PBS) and incubated 
with primary antibodies at room temperature for 1 hour, including mouse anti-
iNOS (BD Biosciences, 610329; 1:100), goat anti-Arginase-1 (Santa Cruz 
Biotechnology, sc-18355; 1:50), rat anti-CD68 (FA-11, Abcam, ab53444; 1:100) 
and rabbit anti-65 subunit of NFκB (H-4, Santa Cruz Biotechnology, sc-109; 
1:100). Alexa Fluor 555 Phalloidin (Thermo Fisher Scientific, A34055; 1:1000) 
was used to visualise cell cytoskeleton for NFκB translocation studies, and 
incubated for 1 hour in the dark at room temperature. Following washes in PBS, 
cells were exposed to fluorescently conjugated secondary antibodies (1:1000, 
Invitrogen) for 1 hour at room temperature prior to counterstaining with 
Hoechst and mounting with Fluoromount-G (Southern Biotech). 
 
2.3.4.	Imaging		
For imaging of primary rat microglia, image acquisition was carried out with a 
20x water immersion objective on an LSM 710 confocal microscope with Zen 





Images were exported to Image J and the pixel intensity of the NFκB staining in 
the nucleus was determined for each cell, with a total average nuclear pixel 
intensity generated for each field of view. Laser power and laser exposure time 
were set using IFN-γ/LPS treated microglia samples (as positive control).  
 
2.3.6.	ELISA	
All reagents from ELISA kits were from R&D Systems. Capture antibodies for 
IGF-1 and TNF-α were diluted in PBS before coating the wells of a 96 well ELISA 
plate and left to incubate at RT overnight. The following day, wells were washed 
with 0.05% Tween (Sigma; P1379) in PBS 3 times before being incubated at RT 
for 1 hour with blocking solutions consisting of 5% Tween in PBS for IGF-1 or 
1% BSA in PBS for TNF-α. Conditioned media were then diluted in 1% BSA in 
PBS 1:2 for IGF-1 or 1:10 for TNF-α, added to the wells and left to incubate for 2 
hours at RT. Standards were diluted in 1% BSA in PBS and a two-fold standard 
curve was created by diluting the most concentrated standard by half in the 
following sample, which was further diluted in half in the following sample and 
so on for 7 wells. Plates were washed thrice in 0.05% Tween in PBS before 
detection antibodies for IGF-1 and TNF-α were diluted in 1% BSA in PBS and 
added to each well for a 2 hour incubation at RT. Following a further three 
washes in 0.05% Tween in PBS, streptavidin was added to each well for 20 mins 
at RT, followed by a further 3 washes and a 20 min incubation with the 
substrate (1:1 ratio of luminol and hydrogen peroxide (Glo Reagents; R&D 
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DY993)) in the dark at RT, at which point 0.16M sulphuric acid was added to 
stop further reactions was added and plates were immediately taken to the 
spectrophotometer for analysis. Absorption of substrate reaction was measured 
for all samples and concentrations of IGF-1 and TNF-α were measured and 




Cerebellum and hindbrain were isolated from P0–P2 CD1 mouse pups and 
sectioned sagittally at 300 μm on a McIlwain tissue chopper. Slices were plated 
onto Millipore-Millicell-CM mesh inserts (Fisher Scientific) in 6-well culture 
plates at 6 slices per insert for immunofluorescence or 3 slices per insert for live 
imaging. Slice culture media consisted of 50% minimal essential media, 25% 
heat-inactivated horse serum, 25% Earle's balanced salt solution (all from 
GIBCO), 6.5 mgml−1 glucose (Sigma), 1% penicillin-streptomycin (Life 
Technologies 15140122), 1% Glutamax (Life Technologies 35050038) and 1% 
HEPES (Invitrogen 15630080), and was changed every 2–3 days.  
 
2.4.2.	Demyelination	with	LPC	
Demyelination was induced at 21 days in	vitro by application of 0.5 
mg.ml−1 lysophosphatidyl choline (LPC; egg yolk, Sigma-Aldrich) for 18-20 




Propidium iodide (25 µg.ml-1, Sigma) was supplemented to the media for the 
last 1 hour prior to fixation, and slices were washed thrice in PBS before fixation 
with 4% PFA in the dark.  
 
2.4.4.	Necrostatin‐1	treatment	
Necrostatin-1 (10 µM, Sigma-Aldrich) was supplemented to media upon LPC 
treatment and in each subsequent media change prior to fixation with 4% PFA. 
1mM necrostatin-1 was encapsulated in lipid nanocapsules (LNCs) by Yasmine 
Labrak (UC Louvrain, Belgium) and used for in	vivo studies.  
 
2.4.5.	Ex	vivo	lineage	tracing		
For both NestinCreTdTomato and CX3CR1CreTdTomato slices, 1µM of 4-
hydroxytamoxifen (4-OHT, Sigma) was supplemented into the media overnight 
to allow efficient cre-recombination. Slices were then washed 3 times, once in 
PBS and twice in fresh media before further incubation for 7 days to allow time 
for residual 4-OHT to be removed from slices (see 2.5.1).  
 
2.4.6.	Immunofluorescent	staining	of	slice	cultures		
All slices prior to staining were fixed in 4% paraformaldehyde (PFA) for 10 
minutes. Slices were then permeabilised and blocked for 1 hour in 5% horse 
serum and 0.3% Triton-X 100 in PBS, and primary antibodies were applied for 2 
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nights at 4°C in a humid chamber. All activated microglia were detected with rat 
anti-CD68 (FA-11, Abcam, ab53444, 1: 100), rabbit anti-IBA-1 (Wako Chemicals, 
019-19741, 1:50) and goat anti-PU.1 (D-19, Santa Cruz Biotechnology, sc5949, 
1:100). Pro-inflammatory microglia were identified with mouse anti-iNOS (BD 
Biosciences, 610329, 1:100) and pro-regenerative microglia identified with goat 
anti-Arginase-1 (M-20, Santa Cruz Biotechnology, sc18355, 1:50). Cell death was 
assessed using rabbit anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100), rat 
anti-MLKL (Merck-Millipore, MABC604, 1:100), rabbit anti-cleaved Caspase-3 
(BD Pharmingen, 559565, 1:100) and mouse anti-cleaved Caspase-1 (P20, Santa 
Cruz Biotechnology, sc22165, 1:100). Remyelination was detected using rat 
anti-myelin basic protein (MBP) (AbD Serotec, MCA409S, 1:250) and chicken 
anti-neurofilament heavy chain (NF-H) (Encor Biotechnology, CPCA-NF-H, 
1:10,000). Nestin+ cells were detected with mouse anti-Nestin (10c2, Abcam, 
ab6142, 1:100). Subsequent to washes in PBS, fluorescently conjugated 
secondary antibodies were applied for 2 h at 20–25°C in a humid chamber (anti-
goat IgG (A21432, A11055), anti-rabbit IgG (A11034, A21206, A10042, 
A11011), anti-rat IgG (A21434, A11006, A21247), anti-mouse IgG (A31570, 
A21235, A31571, A21042), anti-chicken IgG (A11039)) (1:1000 in block, all 
from Invitrogen). Slices were counterstained with Hoechst, mounted on slides 





10 week-old male C57Bl/6J mice were anaesthetised with isoflurane before 
being stereotaxically injected with 0.5 mg.ml−1 lysophosphatidyl choline (LPC) 
diluted in sterile PBS (2µl total) into the corpus callosum (coordinates: 0.5 mm 
lateral, 1.2 mm rostral to Bregma, and 1.4 mm depth to brain surface). Control 
mice underwent the same procedure with a sham injection of 2µl PBS only. Mice 
throughout in vivo experiments were randomly selected for either control or 
treatments, although no particular random selection method was used for this. 
Mice were allowed to recover before sacrifice by intracardiac perfusion-fixation 
at 3, 7, and 10 days post LPC (dpl) with 4% paraformaldehyde (PFA) for 
immunofluorescence, or with cold PBS for flow cytometric analysis. The former 
were post-fixed overnight with 4% PFA, cryoprotected in sucrose (30% in PBS 
for 24 hours, followed by 15% sucrose in PBS for a further 24 hours, all at 4 
degrees), and cryosectioned at 12 µm thickness. For necrostatin-1 in	vivo 
experiments, necrostatin-1 LNCs (1µM, diluted in PBS) or vehicle control LNCs 
(1µM DMSO in PBS) or diD containing LNCs (to visualise which cells 
preferentially take up the LNCs; 1µM in PBS) were co-injected with LPC 
following the same protocol. All LNCs were prepared by Yasmine Labrak and 
colleagues at UCL Belgium. For flow cytometry experiments, lesioning was 
carried out by Claire Davies. All other lesioning experiments were carried out by 





Ai9 (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) mice were crossed 
with C57Bl6-Tg(Nes-CreERT2)KEisc/J to induce tdTomato expression in 
Nestin+ cells. Recombination was induced by 2 subcutaneous injections of 
tamoxifen (2 mg in 200 µl of corn oil; Sigma-Aldrich T5648) 48 hours apart, 5-7 
days prior to brain lesioning as described above. 	
 
2.5.3.	Immunofluorescent	staining	of	focal	lesion	tissue		
Sections of frozen tissue were air dried for 15 minutes before being 
permeabilised and blocked for 1 hour at RT (5% horse serum and 0.3% Triton-
X-100 in PBS) then incubated with primary antibodies overnight at 4°C in a 
humid chamber. Microglia were detected with rat anti-CD68 (FA-11, Abcam. 
Ab53444, 1: 100) and rabbit anti-IBA-1 (Wako Chemicals, 019-19741, 1:50) and 
cell death was assessed using rabbit anti-RIPK3 (Novus Biologicals, NBP1-
77299, 1:100) and rat anti-MLKL (Merck-Millipore, MABC604, 1:100). Nestin+ 
cells were detected with mouse anti-Nestin (Abcam, ab6142, 1:100). Myelin was 
detected with mouse anti-MAG (Merck-Millipore, MAB1567 1:100). Subsequent 
to washes in PBS, fluorescently conjugated secondary antibodies were applied 
for 2h at RT in the dark in a humid chamber (anti-goat IgG (A21432, A11055), 
anti-rabbit IgG (A11034, A21206, A10042, A11011), anti-rat IgG (A21434, 
A11006, A21247), anti-mouse IgG (A31570, A21235, A31571, A21042), anti-
chicken IgG (A11039)) (1:1000, Invitrogen). Slices were counterstained with 





Paraffin-embedded sections of tissue from cuprizone-fed mice were generously 
donated by Tanja Kuhlmann and colleagues (University of Munster). In brief, the 
copper chelator was supplemented into the chow for 6 weeks before then 
allowing mice to feed on normal chow for subsequent 4 weeks. Mice were 
perfused at different time points corresponding to different stages of 
demyelination and remyelination (see Results Chapter 3, Figure 9A). Tissue 
sections underwent deparaffinisation using histoclear (2 x 10 min) and a 
gradient of ethanol (EtOH) concentrations, each for 5 minutes in the following 
order: 2 x 100%, 1 x 95%, 1 x 70% and 1 x 50%, before being washed in tris-
buffered saline (TBS) for 3 x 5 minute washes.  
 
2.6.2.	Immunostaining	protocol		
After deparaffinisation, slides were then placed in vector unmasking solution 
under high heat and pressure for 20 minutes before a final TBS wash. Slides 
were then permeabilised and blocked for 1 hour (5% horse serum (Vector Labs 
S-2012) and 0.3% Triton-X-100 (Fisher Scientific 10254583) in PBS) then 
incubated with primary antibodies overnight at 4°C in a humid chamber. 
Microglia were detected with rat anti-CD68 (FA-11. Ab53444, 1: 100) and cell 
death was assessed using rat anti-RIPK3 (Novus Biologicals, NBP1-77299, 
1:100). Slices were counterstained with Hoechst, mounted on slides and 




Z-stacks of slices were acquired with an Olympus spinning disk confocal 
microscope using either a 20X water immersion or a 60X oil immersion 
objective. Images were collected in Slidebook software (Intelligent imaging 
innovations) and converted to 16 bit .TIFF files for export and analysis. Super-
resolution images were acquired using an LSM880 confocal microscope with 
AiryScan (Centre for Inflammation Research, University of Edinburgh) and a 
63X oil immersion objective. Images were collected in Zen software. For 
analysis, cell counts were done manually with Image J software using the cell 
counter macro. To determine the level of remyelination, a measurement of the 
area of co-localisation of MBP and neurofilament (NFH) staining over the area of 
total NFH staining, known as the remyelination index using Volocity software 
(Perkin Elmer). Volocity was also used to determine the percentage of co-




Focal demyelinated lesions of the corpus callosum were dissected out and 
homogenised with a 2 ml dounce tissue homogeniser in HBSS (Gibco; 
14170088). A Percoll (SLS; 17089102) gradient was used to isolate cells from 
myelin debris. This was done by re-suspending cell pellet in 100% FBS (in 
HBSS) and a 33% isotonic Percol solution (1ml 10X HBSS (Invitrogen 
14185052), 9ml Percol, 20ml 1xHBSS and HEPES (Invitrogen 15630080), and 
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1ml of 10% FBS was overlayed on top of each sample before being spun for 15 
minutes at 800g at 4 degrees). Samples were blocked with Fc-block (LEAF-
purified anti-mouse CD16/32 (Biolegend, 101321)), then incubated with 
fluorochrome-conjugated antibodies CD11b-PeCy7 (eBioscience, 25-0112-82, 
1:100) and CD45-BV605 (Biolegend, 103139, 1:100) for 30 minutes on ice, 
followed by incubation with FITC Annexin-V apoptosis detection kit with 7-AAD 
for 15 minutes at room temperature (Biolegend, 640922, 1:20). Single labelled 
controls were incubated with one antibody only, and an unstained control was 
incubated in block only. Following washes in FACS buffer (481ml HBSS (Gibco 
14170088), 5g BSA (Sigma A1470-25G), 2ml 0.5M EDTA (Ambion AM9260G), 
12.5ml 1M HEPES (Invitrogen 15630080), 4.5ml 10% NaN3 (Sigma-Adrich 
S8032-25G)), samples were run on the BD LSR Fortessa (6 laser) analyser and 
analysed using FlowJo software (FlowJo LLC). Gating was based on initial 
forward and side scatter to eliminate cell debris and clusters, followed by gating 
for singlet cells, then CD11b to gate for myeloid cells, and then CD45lo for 
microglia and CD45hi for macrophages, based on positive controls using LPS-
injected corpus callosum samples carried out by Claire Davies (Miron lab, data 
not shown). At this point, the proportion of each cell type being positive for 
Annexin-V and 7-AAD was analysed to determine proportion of dying cells at 


































SPMS M 64 26 1 1 0 0 
SPMS M 40 9 1 1 1 3 
2 2 2 2 
PPMS M 37 27 1 1 0 4 
SPMS F 57 27 1 1 0 4 
SPMS F 46 25 1 1 1 0 
2 2 0 0 
SPMS F 42 19 1 1 0 2 
 TOTAL	 10	 4	 15	
Control		 Carcinom
a of the 
tongue  





M 82 - 1 - - - 
Cardiac 
failure  
M 64 - 1 - - - 
Ovarian 
cancer  
F 60 - 1 - - - 




Post-mortem tissue from multiple sclerosis (MS) patients and controls that died 
of non-neurological causes were obtained via a UK prospective donor scheme 
with full ethical approval from the UK Multiple Sclerosis Tissue Bank 
(MREC/02/2/39). Diagnosis of MS was confirmed by neuropathological means 
by F. Roncaroli (Imperial College London) and clinical history was provided by 
R. Nicholas (Imperial College London). Snap frozen unfixed tissue blocks (2 × 2 
× 1 cm) were cut at 10 μm and stored at −80°C. Lesions were classi ied 
according to the International Classification of Neurological Disease using Luxol 
Fast Blue staining and CD68+ immunoreactivity (8,	35) which was carried out 
by Anna Williams (Scottish centre for regenerative medicine, university of 
Edinburgh). Following washes in 0.1% Tween-20 (vol/vol) in Tris-buffered 
saline (TBS), sections were microwaved in Vector unmasking solution for 10 
minutes, washed once, and endogenous phosphatase and peroxidase activity 
blocked for 5 minutes (Bloxall, Vector). Primary antibodies were incubated with 
tissue in a humid chamber for 1 hour at RT. Sections were washed in TBS and 
stains visualized by Vector Blue substrate kit according to the manufacturer’s 
instructions (maximum 15 minutes). For co-staining, sections were washed 
thrice and re-blocked to quench any remaining phosphatase activity (Bloxall, 
Vector) prior to application of primary antibody then developed using Vector 
Red substrate kit according to the manufacturer’s instructions (maximum 15 
minutes). Following washes in water, the sections were counterstained with 
Hoechst and mounted with Fluoromount-G. Primary antibodies used include 
mouse anti- CD68 (Dako, M0814; 1:100), mouse anti-Nestin (Santa Cruz 
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Biotechnology, sc23927, 1:100), goat anti-PU.1 (Santa Cruz Biotechnology, 
sc5949, 1:100), and rat anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100). 
	
2.9.3.	Image	acquisition	and	analysis	of	human	tissue		
Entire tissue sections were imaged using a Zeiss AxioScan SlideScanner, and 
lesion maps were prepared for each tissue in Zeiss Zen2 software using Luxol 
Fast Blue-stained sections. 2 fields of 360μm × 360μm were counted per lesion 
and counts were multiplied to determine density of immunopositive cells per 
mm2. The cell counts from the two fields of view (internal replicates) per lesion 
were averaged represented as one data point.  
	
2.10.	Statistical	Analysis	
All manual cell counts for slice cultures, in	vivo lesioned tissue, and MS tissue 
were performed in a blinded manner. Data are represented as mean ± S.E.M 
from a minimum of 3 biological replicates unless otherwise stated. One 
biological replicate is represented by one animal (both in	vivo and ex	vivo/ one 
lesion in a patient. Internal technical repeats are represented by 3 organotypic 
slices (ex	vivo) or slides of tissue from the same animal for in	vivo animal 
studies. Internal replicates for human data were represented by the mean 
counts from 2 360μm × 360μm fields of view per lesion. Each lesion was 
represented as a data point, even if one patient had multiple lesions (due to the 
heterogeneity of all lesions).  All data were first tested for normality prior to 
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performing statistical analyses using a D’Agostino-Pearson normality test 
(Graphpad Prism). Although in	vivo experiments had low (n=3) n numbers due 
to limited resources and animal deaths in some instances, power calculations 
showed >80% power at p<0.05 using a web-based power calculation software 
(https://clincalc.com; see examples below). Multiple comparisons in the same 
data set were analysed by Kruskal-Wallis test with Newman-Keuls post-hoc test 
if non-parametric, or with a one way ANOVA if normally distributed. Single 
comparisons to control were made using Mann-Whitney U test (non-
parametric) or t-tests (parametric). Human tissue data were compared by 
Mann-Whitney U test. P< 0.05 was considered to be statistically significant. Data 
handling and statistical processing was performed using Microsoft Excel and 
GraphPad Prism 6/7 Software.  
Experiment	 Figure		 Comparison Power	 Variance		
Annexin-V+PI+ 
microglia in	vivo 
3.3.5 3 dpl v 7 dpl 100% 3.58724 v 8.283 
7 dpl v 10 dpl 88.51% 8.283 v 98.0892 




(%) in	vivo  
3.3.7 3 dpl v 7 dpl 100% 2.00223 v 
15.5078 
iNOS+ CD68+ 
numbers at 7 dpl 
ex	vivo 
3.3.10 Veh v Nec-1 at 7 
dpl 
100% 0.08335 v 4 
MS tissue MLKL+ 
CD68+ counts  






Antigen	 Species		 Clone		 Source		 Cat	no		 Concentration	
iNOS Mouse  BD Biosciences 610329 1µg/ml 
CD68 Rat FA-11 Abcam Ab53444 5µg/ml 
NFκB P65 Mouse H-4 SCBT Sc-109 2µg/ml 
PU.1 Goat D-19 SCBT Sc5949 1µg/ml 
Arginase-
1 
Goat M-20 SCBT SC18355 5µg/ml 





MLKL Rat  Merck-
Millipore 
MABC604 2µg/ml 
Caspase-3 Rabbit  BD 
Pharminogen 
559656 1µg/ml 
Caspase-1 Mouse P20 SCBT Sc22165 2µg/ml 
MBP Rat  AbD Serotec MCA4095 1µg/ml 
NF-H Chicken  Encor 
Biotechnology 
CPCA-NFH 0.1µg/ml 
Nestin Mouse 10c2 Abcam Ab6442 0.5µg/ml 
IBA-1 Rabbit  Wako 019-19741 0.5µg/ml 






Previous work showed that pro-inflammatory microglial activation after 
demyelination leads to a transition to an anti-inflammatory/ tissue reparative 
phenotype needed for efficient remyelination.  Remyelination failure in MS is 
associated with lesions with abundant pro-inflammatory microglia, and a lack of 
pro-regenerative microglia. In order to be able to promote pro-regenerative 
microglial activation therapeutically in diseases like MS, we first must 
understand how this transition takes place, particularly focusing on the fate of 
pro-inflammatory microglia during efficient remyelination. Here, it is shown in 
multiple models that pro-inflammatory microglia undergo cell death via 
controlled necrosis (necroptosis). Furthermore, blockade of necroptosis with a 
small molecule inhibitor lead to prolonged pro-inflammatory microglial 
activation, consequentially leading to a significant impairment in remyelination. 
Finally, in MS lesions microglial necroptosis is only a significant feature of acute 
lesions with high remyelination potential, and not chronic inactive lesions with 
poor remyelination potential. Taken altogether, this work presents a previously 
unrecognized mechanism of immunomodulation whereby microglia are able to 
rapidly shut down inflammation after injury by undergoing necroptosis. 
Furthermore, impairment of this process may contribute to the prolonged 
inflammation and lack of remyelination in MS lesions. Therefore, pro-
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inflammatory microglial necroptosis may represent a novel therapeutic target 





Microglia are able to adopt a range of functional phenotypes reflective of their 
microenvironment; defined by their interactions with other cell types, exposure 
to particular cytokines, or in response to damage (damage associated molecular 
patterns (DAMPs), alarmins) or infection (pathogen associated molecular 
patterns (PAMPs)). In the context of remyelination, two predominant microglia 
and macrophage phenotypes have been identified by differential gene and 
protein expression and function. After demyelination, microglia first become 
‘pro-inflammatory’ in phenotype, identified by their expression of inducible 
nitric oxide synthase (iNOS), tumour necrosis factor alpha (TNF-α), interleukin-
6 (IL-6), interleukin 1 beta (IL-1β) and FC gamma receptors CD16/32 (7,	8). 
Although it is unclear their exact role in remyelination, it has been shown that 
they are able to promote oligodendrocyte progenitor cell (OPC) migration (in	
vitro) and proliferation (in	vitro and in	vivo)(8). For efficient remyelination to 
take place however, pro-inflammatory microglia must undergo a transition to a 
anti-inflammatory/ pro-regenerative phenotype, identified by expression of 
arginase-1 (Arg-1), mannose receptor, insulin-like growth factor 1 (IGF-1) and 
transforming growth factor beta (TGF-β), shown experimentally to promote 
OPC differentiation into mature myelinating oligodendrocytes (7,	8). Efficient 
remyelination is therefore underpinned by precise temporal activation states of 
microglia, with the resolution of pro-inflammatory microglial responses a vital 
determinant in driving remyelination.  
It is therefore predicted that dysregulation of microglial phenotypes may have a 
significant impact on remyelination. For example, persistent pro-inflammatory 
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expression of genes such as CD16/32, CD86 and IFN-γ are seen in the 
electromechanical displacement spinal cord injury model, which is also 
associated with poor axonal regeneration/ remyelination (80). This suggests 
that unresolved inflammation and chronic pro-inflammatory microglial 
inflammation is detrimental for regeneration. Furthermore, a greater ratio of 
pro-inflammatory microglia compared to pro-regenerative microglia is 
associated with poor axonal regeneration in spinal cord injury (80) and is 
associated with the peak of clinical severity in experimental autoimmune 
encephalomyelitis (EAE) (121). Moreover, chronic inactive lesions in post-
mortem MS tissue (with poor remyelination potential) are associated with an 
abundance of iNOS+ pro-inflammatory microglia and macrophages, whereas 
mannose receptor+ macrophages increased predominantly in actively 
remyelinating lesions (8,	117). Co-culture studies have shown that pro-
inflammatory microglia secrete many inflammatory and reactive molecules 
capable of inducing damage to, and death of, oligodendrocytes and OPCs, 
including nitric oxide (NO2) (154), TNF-α (155‐157), IL-1β (156), and 
peroxynitrite (158). Resolution of inflammatory microglia is therefore 
important for oligodendrocyte health and efficient remyelination.    
Evidence from human tissue and models of CNS demyelination suggests that for 
efficient remyelination to take place, there must be a transition in microglial 
phenotypes from an initial pro-inflammatory/ OPC-proliferative phenotype to 
an anti-inflammatory/ pro-regenerative/ OPC-differentiating phenotype. The 
mechanisms that underpin microglial activation during remyelination remain 
unknown. Although thought to be an in	situ switch in activation in the microglia 
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themselves, this has never been substantiated. Therefore, uncovering the 
cellular and molecular mechanisms that underpin microglial activation states 
during efficient remyelination may represent a novel therapeutic target in 







To delineate the precise timing of microglial activation in the ex	vivo model after 
demyelination, organotypic cerebellar slices derived from developing mouse 
brain were fixed at various times post-LPC throughout remyelination (Figure 
1A). Pro-inflammatory microglia (iNOS+ CD68+) numbers peaked at 12 hours 
post LPC (hpl; Figure 1B, C) whereas pro-regenerative microglia (Arg-1+ 
CD68+) numbers peaked at 7 days post LPC (dpl; Figure 1B, C). At 1 dpl there 
was a significant reduction in CD68+ microglia, a marker of activated microglia 
(Figure 1B, C), as well as pan microglia marker PU.1 at 24 hpl (Figure 1D, E). 
PBS was used as a vehicle control and organotypic slice cultures fixed at 1, 7 and 
14 days post-treatment and showed no fluctuations in CD68+ microglia 
numbers over time (See Chapter 9. Appendix, Figure 1) suggesting that no death 
or repopulation is taking place in the control treated slices, and also 





Figure	1.	A. Schematic of organotypic cerebellar slice culture model of demyelination 
and remyelination. Red arrows indicate time points analysed. B. Fixed slices at 0.5 dpl, 
1 dpl and 7 dpl immunostained for iNOS (green), CD68 (white) and Arg-1 (magenta) 
and counterstained with Hoechst. Scale bar, 20um. C. Mean numbers of microglia from 
0 – 14 dpl ± s.e.m.. N=3 biological replicates.  D. Slices stained for PU.1 (green) at 6 hpl 
and 24 hpl. Scale bar, 20μm. E. Mean numbers of PU.1+ cells in slices from 0 – 24 hpl ± 
s.e.m.. N=3 biological replicates. *p<0.05 24 hpl v 0 hpl (Kruskal-Wallis test, Dunn’s 
Multiple Comparison post-test). N=3 biological replicates. *p<0.05 18 hpl v 0 hpl 





To determine whether cell death was the cause of the reduction in microglia 
numbers in the explants, propidium iodide (PI), we used a fluorescent DNA-
binding dye only able to penetrate cells with a compromised cell membrane, 
thus indicative of cells undergoing cell death (Figure 2A). Organotypic slices 
were live-labelled with PI one hour prior to fixation to identify dying cells. Prior 
to demyelination (0 hpl), very few CD68+ or PU.1+ microglia were PI+ (Figure 
2B-E). However, after demyelination, the proportion of PI+ microglia increased 











Figure	2.	A. Schematic of the mechanism of action of propidium iodide; a fluorescent 
dye able to penetrate cells with a compromised membrane (cells undergoing cell 
death). B. Organotypic slices stained for CD68 (green) and live labelled with propidium 
iodide (PI; red) at 0 hpl and 12 hpl. White arrows indicate microglia (CD68+) positive 
for PI. Scale bar, 20μm. C. Mean percentages of PI+ microglia (represented as a 
percentage of all total CD68+ microglia) from 0  dpl to 24  dpl. * p<0.05 24 hpl vs 0 hpl 
(Kruskal-Wallis test, Dunn’s Multiple Comparison post-test). N=3 biological replicates. 
D. Untreated (0 hpl) and demyelinated (18 hpl) slices live-labelled for PI (red) then 
immunostained for PU.1 (green), double positive cells indicated (arrows). Scale bar, 
10µm. E. Mean percentage of PI+ total microglia (represented as a percentage of all 
total PU.1+ microlglia) from 0 – 24 hpl ± s.e.m.. *p<0.05, **p<0.01 vs 0 hpl (Kruskal-






To determine if the LPC toxin itself can induce microglial cell death, rather than 
a consequence of pro-inflammatory activation during remyelination, primary 
rat microglia were cultured with LPC for 18 hours. Immunostaining revealed no 
decrease in CD68+ cells, nor did microglia express iNOS or Arg-1 in response to 
LPC treatment (Figure 5). This preliminary experiment suggests that LPC alone 
is not sufficient to drive the death or induce the activation of microglia, however 
greater numbers of biological repeats would be needed to draw definitive 
conclusions.  
 
Figure	3. Primary rat microglia treated with LPC for 18 hours immunostained for CD68 








To analyse microglia in an in	vivo model of demyelination, LPC was 
stereotaxically injected into the corpus callosum of adult mice, inducing a focal 
demyelinating lesion which subsequently efficient remyelinates over the next 
14-21 days, as previously demonstrated (8). Lesions were analysed by flow 
cytometry at time points in remyelination corresponding to key events in 
microglial activation (8); 3 dpl associated with a peak in iNOS+ microglia 
numbers, 10 dpl associated with a peak in Arg-1+ microglia numbers, and an 
intermediate time of 7 dpl (Figure 4A). Gating for microglia firstly relied on 
dead cell and cell debris elimination based on forward (FSC-A) and side scatter 
(SSC-A), followed by gating for CD11b+ cells to identify myeloid cells, followed 
by CD45lo expression to distinguish microglia from monocyte derived 
macrophages. CD11b+CD45lo microglia were plotted against 2 cell death 
markers Annexin-V and 7-Aminoactinomycin D (7-AAD) to identify proportions 
of dying microglia at each time point post demyelination (Figure 4B). 
Unfortunately there was no positive control generated for death markers and 
therefore the gates for Annexin-V and 7-AAD were set based on the sham 









Figure	4.	A. Schematic of the in	vivo focal demyelination lesion model. B. Gating 
strategy for microglia from in	vivo lesions; using forward (FSC-A) and side scatter (SSC-
A) to gate all living cells, excluding debris; myeloid cells detected with CD11b 
expression; detection of microglia based on low expression of CD45; detection of cell 









Analysis of the microglia from the lesion site revealed a significant decrease in 
microglia numbers from 3 dpl to 7 dpl and 10 dpl (Figure 5A). CD11b+CD45lo 
microglia were then analysed for cell death using Annexin-V and 7-AAD. There 
was a significant increase in the proportion of microglia positive for both cell 
death markers at 7 dpl compared to 3 dpl, which then decreased at 10 dpl 
(Figure 5B, D, E). Microglial death was not a result of the mechanical injury 
inflicted by the stereotaxic injection, as microglia from sham control mice 
(injected with needle containing PBS of the same volume and for the same time 
as LPC treated mice) at 7 dpl were negative for Annexin-V and 7-AAD (Figure 
5C). Therefore, the observed loss of microglia from 7dpl, after the peak in pro-










Figure	5.	A. Mean numbers of CD11b+CD45lo cells at 3, 7 and 10 dpl ± s.e.m. *P=0.0141 
3 dpl vs 7 dpl, *P=0.0127 3 dpl vs 10 dpl (unpaired Student’s t-test). N=3 mice per time 
point. B. Flow cytometry plots of lesion-isolated microglia (CD11b+ Cd45lo) positive for 
cell death markers Annexin-V and 7-AAD at 3, 7, and 10 dpl. C. Flow cytometry plot of 
sham injection (7 dpl) mouse tissue gated for microglia and plotted with cell death 
markers Annexin-V and 7-AAD. D. Mean numbers of Annexin-V+7-AAD+ microglia at 3, 
7 and 10dpl ±s.e.m. *P=0.029 (Kruskal-Wallis test). N=3 mice per time point E. Mean 
proportion of all microglia which are Annexin-V+ 7-AAD+ (represented as a percentage 
of total CD11b+CD45+ cells) at 3, 7 and 10 dpl ± s.e.m. ****P<0.0001 3dpl vs 7 dpl , 






The mechanism by which microglia were dying was investigated. Apoptosis as 
detected by terminal deoxynucleotidyl transferase dUTP nick-end labelling 
(TUNEL; red) and cleaved caspase 3 (green) staining revealed the majority of 
PU.1+ microglia were negative at 12 hpl, compared to ethanol-treated (EtOH) 
positive control organotypic slices (Figure 6A). Microglia showed constitutive 
cleaved caspase-1 expression (a marker of inflammatory cell death mechanism 
pyroptosis) in CD68+ microglia even prior to demyelination (0 hpl, Figure 6B), 
suggestive of a role in non-death related mechanisms. Microglial death after 
demyelination therefore is not via apoptosis or pyroptosis.  
 
 
Figure	6.	A. Ethanol-treated organotypic cerebellar slice (left) as a positive control to 
induce apoptosis and demyelinated slice at 12 hpl immunostained for cleaved caspase-
3 (green), TUNEL assay (red) and PU.1 (white). Scale bar, 10μm. B. Organotypic 
cerebellar slices untreated (0 hpl) (left) and LPC-treated at 12 hpl (right) 
immunostained for CD68 (green) and Cleaved Caspase-1 (red). Arrows indicate 






We next investigated necroptosis, a programmed necrosis driven by formation 
of the necroptosome comprised of receptor-interacting serine/threonine-
protein kinases (RIPK) 1 and 3, leading to phosphorylation of mixed lineage 
kinease domain like pseudokinase (MLKL) and formation of pores in the cell 
membrane (159) (Figure 7A). Immunostaining ex	vivo tissue for MLKL revealed 
a significant increase in MLKL+IBA-1+ microglia at 12 hpl, prior to the observed 
loss of cells (Figure 7B, C). Similarly, immunostaining for RIPK3 in the in	vivo 
lesion tissue revealed a significant proportion of microglia at 3 dpl that were 
RIPK3+ compared to 7 dpl and time-matched sham control (3dpl) (Figure 7D, E) 
as detected by percentage of co-localisation of the two markers.  Quantification 
of 3 sham controls and comparing levels of RIPK3+ microglia from mechanical 
injury alone would demonstrate basal microglial necroptosis levels, and should 
be included in future experimentation. Accordingly, high co-localisation of 
MLKL and IBA-1 was observed at 3dpl compared to 7dpl (Figure 7F, G), 
although further repeats are warranted. Nevertheless, increased expression of 
both RIPK3 and MLKL in microglia prior to the loss of the cells in both models 






Figure	7.	A. Simplified schematic of TNF-α induced necroptosis pathway. B. Untreated 
(0 hpl) and LPC-treated slices (12 hpl) immunostained for IBA-1 (green) and MLKL 
(red), double positive cells indicated (arrows). Magnified example of a selected IBA-1+ 
MLKL+ cell (box; right) at 12 hpl. Scale bar, 10µm. C. Mean number of MLKL+ microglia 
(IBA-1+) at 0, 6 and 12 hpl ± s.e.m.. *p<0.05 12 hpl vs 0 hpl (Kruskal-Wallis test, Dunn’s 
Multiple Comparison post-test). N=3 biological replicates. D. In	vivo lesioned corpus 
callosum (dotted outline) at 3 and 7 dpl, along with a sham injection (7 days post 
injection) stained for RIPK3 (green) and CD68 (red). Inset at 3 dpl shows RIPK3+ 
CD68+ cell. Scale bar, 50µm. E. Mean percentage of RIPK3+ CD68+ microglia / total 
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CD68+ microglia at 3 and 7 dpl ± s.e.m.. *P=0.0002 (unpaired Student’s t-test). N=3 
mice per time point. F. Image of corpus callosum lesion stained for MLKL (red) and IBA-
1 (green) at 3 and 7 dpl. Arrows indicate MLKL+ IBA-1+ microglia. Scale bar, 10µm. G. 
Percentage of MLKL+ IBA-1+ microglia (represented as a percentage of total IBA-1+ 



















Monocyte-derived macrophages have been shown to migrate into the 
demyelinated lesion site in this model (8). Therefore, to determine if 
macrophages also undergo necroptosis in this model, Ccr2RFP/+ mice underwent 
LPC-induced demyelination (carried out by Claire Davies, Miron Lab), and Ccr2+ 
macrophages that express RFP can be distinguished from Ccr2-RFP negative 
microglia in the CNS (Figure 8A). Immunostaining of Ccr2-RFP lesions with 
necroptosis marker RIPK3 revealed that Ccr2-RFP+ macrophages represented 
only ~25% of all RIPK3+ cells at 3dpl (Figure 8B, C). Interestingly, at 10dpl, a 
marked decrease in Ccr2-RFP+ macrophages were  present, and these cells only 
represented ~10% of total RIPK3+ cells at this time (Figure 8B, C), suggesting a 
proportion of macrophages had undergone necroptosis. However, macrophage 
migration out of the lesion area cannot be ruled out. Overall this demonstrates 




Figure	8.	A.	Schematic of Ccr2-RFP+ monocytes migrating to the CNS and 
differentiating into Ccr2-RFP+macrophages. B. Images from lesion areas with Ccr2-
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RFP+ macrophages (red) and immunostained with RIPK3 (green) at 3dpl and 10dpl. 
Scale bar, 20µm. C. Quantification of Ccr2+ RIPK3+ cells and Ccr2 negative RIPK3+ cells 






To determine whether we could associate microglia necroptosis with 
remyelination in a distinct model of myelin damage, tissue from the cuprizone 
model was investigated for necroptotic microglia. In this model, the copper 
chelator cuprizone is supplemented into the chow of mice for 6 weeks, inducing 
demyelination particularly in the corpus callosum in the first 3 weeks, followed 
by concurrent demyelination and remyelination in the second 3 weeks (160). At 
this point, the mice are returned to a normal diet for 4 weeks where 
remyelination (without demyelination) takes place (Figure 9A). 
Immunostaining revealed that RIPK3+ CD68+ microglia were significantly 
increased at the onset of early remyelination and decreased once remyelination 
was complete (Figure 9B, C). Staining of tissue during demyelination and early 
remyelination revealed microglia (IBA-1+) were also MLKL+ (Figure 9D), 








Figure	9.	A. Schematic of the treatment regimen for the cuprizone model of 
demyelination and remyelination. B. Number of RIPK3+ CD68+ microglia in mice 
treated with cuprizone from various phases of demyelination and remyelination: 
demyelination-only, demyelination and remyelination, remyelination only phases (1.5 
wks post return to normal diet, 4 wks post return to normal diet) ± s.e.m.. *P=0.0365 
for demyelination & remyelination vs demyelination only (Kruskal-Wallis test, Dunn’s 
Multiple Comparison post-test). N=3 mice per time point and condition. C. Images from 
cuprizone tissue during demyelination only phase (top panel) and ongoing 
demyelination and remyelination phase (bottom panel) immunostained for CD68 (red) 
and RIPK3 (green). Scale bar, 50μm. D. Representative image from cuprizone tissue 
during ongoing demyelination and remyelination immunostained for MLKL (red) and 







To investigate the importance of microglial necroptosis during efficient 
remyelination, Necrostatin-1, a small molecule inhibitor of necroptosis that 
prevents necroptosome formation via the inhibition of RIPK1 activity (Figure 
10A) was supplemented from the onset of demyelination. Necrostatin-1 
treatment prevented microglia (CD68+) loss at 1 dpl compared to vehicle 
control (Figure 10B, C), and also prolonged iNOS expression in the microglia at 
7 dpl when the transition to the pro-regenerative phenotype would normally 
have taken place (Figure 10B, D). Preventing microglia necroptosis also 
significantly hindered remyelination in the explants at 7 and 14 dpl, compared 
to the robust remyelination observed in the vehicle control (Figure 10E, F). 
Remyelination was detected by measurement of Neurofilament (NF-H) and MBP 
co-localisation as a proportion of total NF-H staining (remyelination index), 
with 1.0 being a measurement of total co-localisation of all NF-H+ axons with 
MBP (Figure 10F). Therefore, inhibition of necroptosis prevented pro-







Figure	10.	A. Schematic of a simplified necroptosis pathway with small molecular 
inhibitor of necroptosis, necrostatin-1, inhibiting RIPK1 activation. B. Demyelinated 
slices treated with vehicle (VEH; left) or necrostatin-1 (NEC-1; right) at 1 and 7 dpl 
immunostained for CD68 (red) and iNOS (green). Scale bar, 10µm. C. Mean number of 
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CD68+ microglia in NEC-1- or VEH-treated conditions at 1, 7 and 10 dpl ± s.e.m..	D. 
Mean number of iNOS+ microglia (CD68+) at 1, and 7 dpl in NEC-1- or VEH-treated 
conditions ± s.e.m.. *P=0.05 vs VEH (Mann Whitney test). N=3 biological replicates per 
time point and condition. E. Demyelinated slices treated with VEH (left) or NEC-1 
(right) at 1 and 7 dpl immunostained for myelin (MBP; red) and axons (NF-H; green). 
Scale bar, 20µm. F. Remyelination index of VEH- and NEC-1-treated slices at 1, 7 and 14 
dpl ± s.e.m.. *P=0.0159, **P=0.0079 vs VEH (Mann Whitney test). N=5 biological 


















As necroptosis of oligodendrocytes and neurons has been observed in MS (97) 
and Alzheimer’s Disease (161), respectively, we assessed whether this was 
occurring in our acute model of demyelination in the slice culture. Demyelinated 
slices were stained for oligodendrocyte lineage marker Olig2, neuronal marker 
NeuN, and necroptosis marker RIPK3. At 18 hpl, <3% of total oligodendrocytes 
or neurons were positive for RIPK3 (Figure 11A-D) showing that necroptosis in 










Figure	11.	A. Demyelinated slice at 12 hpl immunostained for oligodendrocyte lineage 
marker Olig2 (green) and RIPK3 (red). Scale bar, 20μm. B. Mean numbers of Olig2+ 
cells and Olig2+RIPK3+ cells ±sem.. N=3 biological replicates. C. Demyelinated slice at 
12 hpl immunostained for neuronal marker NeuN (green) and RIPK3 (red). Scale bar, 







In order to specifically inhibit microglial necroptosis during remyelination in	
vivo, lipid nanocapsules (LNCs) containing the fluorescent molecule diD (made 
by Anne des Rieux’s lab (Yasmine Labrak); Louvain University, Belgium) were 
first used to detect specificity of LNC uptake in microglia compared to other cell 
types during remyelination (Figure 12A). diD (a fluorescent dye) containing 
LNCs were co-injected with LPC into the corpus callosum to ensure direct lesion 
penetrance, and lesions were immunostained at 3 dpl to determine if microglia 
preferentially phagocytosed LNCs over other cell types.  At 3 dpl, the majority of 
diD LNC accumulation was associated with IBA-1+ co-expression, with minimal 
(>5%) accumulation in astrocytes (GFAP; Figure 12B, D) or cells of the 
oligodendrocyte lineage (CC1; Figure 12C, D), therefore identifying LNCs as an 






Figure	12.	A. Schematic of experimental plan for in	vivo delivery of LNCs containing 
diD and LPC via stereotaxic injection into corpus callosum. B. Representative image of 
demyelinated lesion area at 3dpl of mice injected with LNCs containing fluorescent dye 
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diD (white) and immunostained with IBA-1 (red) and astrocyte marker GFAP (green) 
to show specificity of LNC delivery. Scale bar, 20μm. C. Representative image of 
demyelinated lesion area at 3dpl of mice injected with LNCs containing fluorescent dye 
diD (white) and immunostained with IBA-1 (red) and oligodendrocyte lineage marker 
CC1 (green) to show specificity of LNC delivery. Scale bar, 20μm. D. Mean proportion of 
IBA-1, GFAP and CC1+ cells positive for diD clusters (represented as a percentage of all 







Necrostatin-1 and vehicle control (DMSO) were encapsulated into LNCs and co-
injected with LPC (Figure 13A). Compared to vehicle control (Veh LNCs), 
necrostatin-1 (NEC-1 LNCs) treatment lead to a decrease in IBA-1+/MLKL co-
localisation at 3 dpl (Figure 13B), indicative of necrostatin-1 treatment 
inhibiting necroptosis pathway activation. At 10 dpl, there were 2-fold greater 
numbers of microglia (identified by expression of microglia-specific marker 
Tmem119) in NEC-1 LNC treated mice compared to vehicle LNC treated mice 
(Figure 13C), suggestive of a prevention of microglial death in NEC-1 treated 
mice. Furthermore, NEC-1 treatment lead to a significant increase in the 
percentage of iNOS+ Tmem119+ microglia, and a significant reduction in the 
percentage of Arg-1+ Tmem119+ microglia at 10 dpl compared to vehicle 
treated demyelinated lesions (Figure 13C, raw values in Chapter 9 Appendix, 
Figure 2). This suggests that NEC-1 treatment prevented pro-inflammatory 
microglial necroptosis, leading to a prolonged presence of pro-inflammatory 
microglia and an inhibition of pro-regenerative microglial activation. 
Importantly, immunostaining for myelin protein MAG (myelin associated 
glycoprotein) revealed a stark reduction in NEC-1 treated mice compared to 
vehicle, as measured by mean MAG pixel intensity of the lesion area at 10 dpl 
(Figure 13D, E), indicating that NEC-1 treatment in microglia had significantly 
inhibited oligodendrocyte differentiation (suggestive of remyelination) in	vivo. 
Taken altogether, this evidence suggests that we have effectively targeted 
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microglia using LNCs, and specific inhibition of microglial necroptosis prevents 
microglial death, maintains pro-inflammatory (iNOS) activation, and prevents 
pro-regenerative (Arg-1) microglial activation, consequentially inhibiting 
oligodendrocyte differentiation, and therefore remyelination. However, to 
definitively show that remyelination is inhibited, electron microscopy would be 
needed. Unfortunately with time constraints for this project, this was unable to 









Figure	13.	A. Schematic of experimental plan for in	vivo delivery of LNCs containing 
Necrostatin-1 or vehicle (Veh; DMSO) control and LPC via stereotaxic injection into 
corpus callosum B. Images of lesions at 3 dpl (dotted outline) subsequent to treatment 
with Veh LNCs or NEC-1 LNCs, stained for IBA-1 (green) and MLKL (red). Scale bar, 50 
µm. C. Quantification of the number of Tmem119+ cells, the percentage of iNOS+CD68+ 
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(of total CD68+) cells and the percentage of Arg-1+CD68+ (of total CD68+) cells in 10 
dpl lesions subsequent to treatment with NEC-1 LNCs, represented as fold change over 
values in Veh LNC treated mice. One sample t-test compared to a hypothetical value of 
1: *P=0.0395 for Tmem119+ cells, 0.026 for percentage of iNOS+CD68+ cells, and 
0.0224 for percentage of Arg-1+CD68+ cells. N=3 mice per stain. D. Images of corpus 
callosum at 10 dpl (dotted outline) subsequent to treatment with Veh LNCs or NEC-1 
LNCs stained for myelin protein MAG (white). Scale bar, 20 µm. E. Mean MAG pixel 
intensity in lesions at 10 dpl following injection with Veh LNCs or NEC-1 LNCs. 2-tailed 

















To  investigate the importance of microglial necroptosis during remyelination in 
the human disease, MS lesions of different subtypes including remyelinated 
lesions, lesions with ongoing remyelination/ high potential for remyelination 
(“active“), and lesions with failed remyelination/ low potential for 
remyelination (“chronic inactive“), as described previously (162) were analysed 
and compared to the white matter of post mortem tissue from patients who had 
died of non-neurological causes (“control”) (see Chapter 2: Methods, Table 1 for 
all human tissue information). Only in active lesions were there signicant 
increases in RIPK3+ and MLKL+ CD68+ microglia compared to control white 
matter (Figure 14A-E). Therefore, microglial necroptosis is a feature of active 
MS lesions associated with high numbers of macrophages and a high incidence 
of remyelinaton (163), whereas inactive lesions have signfiicantly fewer 
necroptosing microglia. Therefore, there may be an association of microglial 





Figure	14.	A. Control brain tissue and active MS lesion immunostained for CD68 (blue) 
and RIPK3 (red), counterstained with Hoechst (turquoise). White arrows indicate 
CD68+RIPK3+ cells. Scale bar, 20μm.  B. Magnified view of MLKL expression (red) in a 
microglia (CD68+; blue) in an active lesion, counterstained with Hoechst (turquoise). 
White arrows indicate CD68+MLKL+ cells. C. Magnified view of RIPK3 expression (red) 
in a microglia (CD68+; blue) in an active lesion, counterstained with Hoechst 
(turquoise). White arrows indicate CD68+RIPK3+ cells D. Mean density of RIPK3+ 
microglia (CD68+) per mm2 in control, active, chronic inactive and remyelinated MS 
lesions. Individual data points represent separate lesions. *P=0.0357 active lesions vs 
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control (Mann-Whitney test). Remyelinated v control p=0.1429; chronic inactive v 
control p=0.1029 (Mann-Whitney test).  E. Mean density of MLKL+ microglia (CD68+) 
per mm2 in control, active, chronic inactive and remyelinated MS lesions. Individual 
data points represent separate lesions (see Table 1). *P=0.0226 active lesions vs 
control (Mann-Whitney test). Remyelinated v control p=0.4169; chronic inactive v 





I sought to determine the cellular and molecular mechanisms underpinning 
microglia transition during efficient remyelination from an initial pro-
inflammatory phenotype to a pro-regenerative phenotype. Prior to this 
transition in phenotype, pro-inflammatory microglia undergo necroptosis, as 
shown by a loss of microglia after the peak of pro-inflammatory microglial 
activation, the expression of necroptosis markers MLKL and RIPK3, and the 
inhibition of death using an inhibitor of necroptosis. By blocking microglial 
necroptosis, microglia persist in a pro-inflammatory activation state for 
significantly longer and as a consequence, remyelination is hindered. Therefore, 
for efficient remyelination to take place, pro-inflammatory microglia must 
undergo necroptosis, which may play a role in rapidly shutting down 
inflammation and allowing for the activation of pro-regenerative microglia to 
drive remyelination. I propose that pro-inflammatory microglial necroptosis is a 
previously unrecognised mechanism in which microglial phenotypes are 
regulated during remyelination.  
Using LPC to induce demyelination in the ex	vivo and in	vivo models permits 
investigations of efficient remyelination without concurrent demyelination. 
Although LPC is a myelin toxin, there is evidence to show how it can directly 
influence microglial activation and behaviour. For example, LPC has been shown 
to activate caspase-1 in microglia pre-stimulated with inflammatory 
lipopolysaccharide, a bacterial membrane protein known to induce a potent 
inflammatory response in immune cells including microglia (164). In the 
developing zebrafish brain, LPC released from apoptotic neurons is required at 
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least in part to promote the migration of microglia precursors to colonise the 
brain (165).  However, I did not observe a toxic effect of LPC directly on 
microglia in	vitro	(Figure 3), and also associated microglial necroptosis with 
initiation of remyelination in a model without LPC (Cuprizone, Figure 9). 
Additionally, microglia from demyelinated slices at 12 hpl were negative for 
apoptosis markers TUNEL and cleaved caspase-3 (Figure 6A), and displayed 
constitutive caspase-1+ expression even prior to demyelination (0 hpl, Figure 
6B). Indeed, cleaved caspase-1 has been previously shown to be upregulated in 
LPS and ATP- treated activated microglia in	vitro,	indicative of activated 
inflammasome in the absence of cell death (166).  Furthermore, activated 
(CD68+) microglia are prevalent in myelinated slices prior to demyelination 
(Figure 6B). This may be in response to the mechanical damage associated with 
slicing of the brain sections for culture, and therefore may explain the presence 
of cleaved caspase-1 expression and inflammasome activation in microglia from 
non-demyelinated slices.   
Necroptosis has only recently been identified as a type of programmed cell 
death involved in many pathologies (97,	167,	168). Attention was brought to this 
mechanism when in	vitro experiments with TNF-α treatment caused cultured 
cells to exhibit features of both apoptotic and necrotic death; they appeared to 
have a swollen ‘balloon-like’ morphology (a necrotic cell characteristic), yet 
underwent autophagy (commonly seen in apoptotic cells; (169)). Now it is 
appreciated that many other factors can trigger cells to undergo necroptosis 
including ischemia-reperfusion (170), viral and bacterial infection (171‐173) 
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and it has been observed in neurodegenerative diseases including amyotrophic 
lateral sclerosis (ALS) (168), MS (97), and Alzheimer’s Disease (AD) (161).   
Although similar factors can trigger other cell death mechanisms, the 
downstream molecular pathways underpinning necroptosis distinguish it as a 
unique controlled cell death mechanism (Figure 7A, Diagram	4). Similarly to 
apoptosis, necroptosis can be initiated by the binding of CD95 and CD95L (FAS 
and FASL), TNF receptor 1 and 2 (TNFR1 and TNFR2), TNF-related apoptosis 
inducing ligand receptor 1 and 2 (TRAIL1 and TRAIL2), and pathogen 
recognition receptors (PRRs) involved in the detection of pathogens or PAMPs 
(174), with TNFR1 mediated necroptosis being the most extensively studied. 
Although each trigger will initiate a distinct downstream activation pathway, all 
can converge to activate the necroptosome, and ultimately, necroptosis. 
Comprised of receptor interacting protein kinase-1 and 3 (RIPK1 and RIPK3) 
and pseudokinase mixed lineage kinase like (MLKL), the necroptosome is the 
most downstream, and ultimate initiator of necroptosis (Figure 7A). In response 
to receptor activation, and intracellular death domains including TNFR-
associated death domain (TRADD), caspase-8 cleaves both RIPK1 and RIPK3, 
rendering them inactive, either eliciting an inflammatory response (if cellular 
inhibitors of apoptosis (cIAPs) or and linear ubiquitin chain assembly complex 
(LUBAC) are present) or by driving apoptosis (if deubiquitilyases are present, 
leading to the destabilisation of the inflammatory complex). In the absence of 
caspase-8 activity, deubiquitilyated RIPK1 can form a complex with RIPK3 
which is then able to interact via the RIP homotypic interaction motif (RHIM) 
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present on both kinases (175) leading to the auto-phosphorylation of RIPK3, 
and subsequently leading to the phosphorylation of MLKL. Upon 
phosphorylation, MLKL forms a large oligomeric complex, thought to function as 
a platform at the plasma membrane, allowing for the recruitment of Ca2+ or Na+ 
ion channels (176,	177), and also as a direct pore-forming complex that is 
recruited to the cell membrane causing direct damage (178). Not only the 
executioner of necroptosis, MLKL has also been shown to trigger the formation 
of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, required 
to process and activate interleukin-1 beta (IL-1β), a potent inflammatory 
mediator (179). The membrane disruption caused by MLKL then allows efficient 
efflux of IL-1β (179), suggesting a mechanism responsible for the inflammatory 
response elicited as a consequence of necroptosis.  
Although inflammasome activation is an important part of pro-inflammatory 
microglial responses (180), the loss of microglia and confirmation of cell death 
with PI, 7-AAD and Annexin-V in our models (Figure 5) suggest that MLKL is 
also initiating necroptosis during remyelination, not just inflammasome 
activation.  However, this highlights the need to detect necroptosis not just by 





Diagram	4. Outline of how a single stimuli can trigger inflammation, apoptosis or 
necroptosis. In this example, TNF-α bound to TNFR1 can recruit TRADD and RIPK1. 
cIAPs and LUBAC can stabilise the complex, leading to recruitment of NFκB, and 
activation of its signalling pathway complexes involved in cell survival, inflammation 
and proliferation. Further stimulation leads to deubiquitylation of this complex and 
initiation of caspase-8 dependant forms of apoptotic cell death. In the absence of 
caspase-8 activity, deubiquitylated RIPK1 can recruit RIPK3, leading to the recruitment 








It is important to note however that activation of necroptosis markers does not 
always lead to death of the cell. For example, RIPK1 plays promiscuous roles in 
regulating inflammation and apoptosis as well as necroptosis (Figure 14) (174). 
Post-translational modifications of RIPK1 means there are 4 variants involved 
in different processes, including TNFR1 dependent pro-inflammatory signalling 
by its role in a receptor-bound complex known as complex 1 (181), leading to 
the activation of MAPK and NFκB and their consequential roles in survival and 
inflammation. De-stabilisation of complex 1 leads to cell death, either by a 
caspase-8 dependent and RIPK1-independent form of apoptosis, a RIPK1 and 
caspase-8 dependant form of apoptosis, or by necroptosis via the necroptosome 
(174,	182). In some circumstances, such as in the presence of viral DNA, 
necroptosis can take place independent of RIPK1 (183). Therefore, this further 
highlights that the detection of necroptosis should include the assessment of 
expression of multiple markers of necroptosis (particularly MLKL), the 
detection of cell death itself, and the inhibition of death by necroptosis 
inhibitors such as necrostatin-1.  
Although RIPK3+ Ccr2-RFP+ macrophages were present in the lesion site at 3 
dpl, (Figure 8B, C), it cannot be fully determined if macrophages also undergo 
necroptosis during this time. Indeed, there is a reduction in the number of Ccr2-
RFP+ cells at 10 dpl compared to 3 dpl, although migration out of the lesion site 
cannot be ruled out. There is evidence that macrophages can undergo 
necroptosis, and evidence to suggest that this mechanism is important in 
regulating macrophage phenotypes. Liver-resident macrophages (Kupffer cells) 
from mice infected with Listeria	monocytogenes undergo necroptosis after 
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phagocytosis of the bacteria, as shown by detection of PI+ Kupffer cells and 
inhibition of death by flow cytometry with necrostatin-1 treatment (172). 
Furthermore, Kupffer cell necroptosis then leads to recruitment of monocytes 
able to differentiate into tissue-reparative macrophages, as shown by 
upregulation of Arg‐1 and Ym1 (172). Whether macrophages in the CNS can 
definitively undergo necroptosis, and its importance in driving a pro-
regenerative environment remains to be determined (see	future	directions).  
Inhibition of cell death with necrostatin-1 supports the hypothesis that pro-
inflammatory microglia undergo cell death via necroptosis during 
remyelination. However, supplementing necrostatin-1 treatment into explant 
culture media exposes all cells to potential necrostatin-1 treatment, which may 
confound any observable results on remyelination if other cell types are also 
undergoing necroptosis during this time. Indeed, expression of RIPK1, RIPK3 
and MLKL is prevalent in oligodendrocytes in post mortem MS tissue and in EAE 
(97). However we found that only ~3% of Olig2+ cells were RIPK3+ after LPC 
treatment of slices (Figure 10A, B) and therefore unlikely to impact 
remyelination.  Additionally, neuronal necroptosis has been shown to drive 
neurodegeneration in AD (184), however we found minimal NeuN+ neurons 
positive for RIPK3 after LPC treatment (Figure 10C, D).  
Although my ex	vivo evidence suggests that necroptosis in remyelination is 
predominantly in microglia, I aimed to produce a specific microglial-targeted 
inhibition of necroptosis in	vivo. For this, necrostatin-1 encapsulated inside lipid 
nanocapsules (LNCs) were produced by Yasmine Labrak  (UC Louvain, 
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Belgium), shown previously to be preferentially taken up by phagosomes (185), 
and therefore predominantly by microglia in the CNS. To my knowledge, this 
was the first time that LNCs have been administered at the onset of 
demyelination (by co-injection with LPC) and therefore presented potential 
logistical issues, such as toxicity at high doses, and unknown degradation rates 
in	vivo. Although toxicity of LNCs alone was not measured in these experiments, 
prior experiments from the des Rieux lab concluded that concentrations of LNCs 
above 1µM were cytotoxic, and therefore a maximum concentration of 1µM was 
used for these experiments. Although Veh LNC treated mice showed similar 
microglial activation dynamics and remyelination to LPC treatment alone, 
toxicity of empty LNCs alone and with LPC should be investigated (see	future	
directions). Nonetheless, a single treatment of necrostatin-1 LNCs was sufficient 
to prevent pro-inflammatory microglial necroptosis, as shown by reduction in 
loss of microglia (Tmem119+), prolonged expression of iNOS and reduction of 
Arg-1 at 10 dpl compared to vehicle (Figure 13B, C, Chapter 9 Appendix figure 
2). NEC-1 LNC treatment also significantly reduced remyelination at 10 dpl, as 
shown by intensity of MAG staining (indicative of oligodendrocyte maturation 
and potential remyelination; Figure 13D, E) compared to vehicle, suggesting 
that remyelination is significantly inhibited by specific inhibition of microglial 
necroptosis. Although the differences in MAG pixel intensity are stark in NEC-1 
LNC treated mice compared to Veh LNC treated mice at 10 dpl, closer inspection 
of remyelination by electron microscopy, the gold standard in measuring 
remyelination, should be used in the future (see	future	directions).  
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It cannot be underestimated however that necrostatin-1 itself may have some 
off-target effects including the inhibition of indoleamine-2,3-dioxygenase (IDO), 
an immunomodulatory enzyme found to be important particularly in 
inflammation-associated tumorigenesis (186), and therefore inhibition of  which 
may have the potential to affect inflammatory activation in microglia outside of 
modulation of necroptosis. In more recent years, more specific necrostatins 
have been synthesised, including necrostatin-1s which does not interact with 
IDO (186), and therefore any future studies inhibiting necroptosis should be 
carried out using the newer generation of more specific necrostatins. However, 
the various roles of RIPK1 in non-necroptosis pathways may result in off-target 
effects of necrostatins despite greater RIPK1 specificity (159). Although 
necrosulfonamide has been identified as a potent inhibitor of necroptosis via its 
selective inhibition of MLKL, and therefore a more specific inhibitor of 
necroptosis in general, it is unclear if the small molecule inhibitor is able to 
target mouse MLKL, as studies to identify the compound were done in human 
cell lines (187).  However, a recent paper reported how necrosulfonamide 
treatment in a mouse model of spinal cord injury is protective for spinal cord 
neurons, although its direct effect on reducing MLKL activity was not measured 
(188). Therefore, the lack of uncertainty to the specificity of necroptosis specific 
inhibitors warrants a genetic mouse model. For example the use of a microglial-
specific inducible Mlkl knockout mouse may provide an even more specific and 
straightforward means of inhibiting microglial necroptosis in the future (see	
future	directions).    
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It is now appreciated that necroptosis is a common feature in many 
neurodegenerative diseases and in different cell types. Evidence suggests that 
neuronal necroptosis potentiates the progression of disease in AD. Indeed, post 
mortem analysis of brains from AD patients revealed significantly increased 
levels of necroptosis proteins RIPK3 and MLKL, as well as phosphorylated, and 
therefore active MLKL compared to control (161). Co-staining revealed ~60% of 
pMLKL+ cells were neurons (indicated by NeuN staining), 28% were microglia 
(IBA-1+) and 11% were astrocytes (GFAP+)(161). Furthermore, mRNA 
expression levels of necroptosis markers Ripk1 and Mlkl	correlated negatively 
with brain weight and Braak staging, a measurement of pathology, suggesting a 
detrimental effect of necroptosis on the progression of AD (161), although 
individual cell type gene expression was not assessed, and therefore the role of 
microglial necroptosis remains unclear. Moreover, post mortem MS samples 
showed an increase in necroptosis proteins RIPK3, MLKL and pMLKL, and 
importantly, increases in protein aggregates of MLKL compared to control (97), 
indicative of MLKL oligomerisation and execution of necroptosis (159,	178). 
Immunostaining revealed increases in RIPK1+ and MLKL+ CC1+ 
oligodendrocytes in MS tissue and cuprizone-induced demyelinated mouse 
tissue.  Inhibition of necroptosis by necrostatin-1 analogue 7N-1 or RIPK3 
knockout mice protected oligodendrocytes from death in cuprizone model, 
showing how necroptosis can be detrimental and blocking necroptosis may be 
of therapeutic benefit in some cell types (97). MS tissue samples also revealed 
RIPK1+ and MLKL+ IBA-1+ microglia, albeit to a much lesser extent, although 
different lesion types were not analysed. Evidence from this thesis suggests that 
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there are indeed significant differences in RIPK3+ and MLKL+ microglia 
depending on lesion types, with more RIPK3+ and MLKL+ microglia present in 
active lesions associated with high macrophage infiltration and potential for 
remyelination (163) (Figure 14), suggesting a role of microglial necroptosis in 
efficient remyelination in MS. Importantly, global inhibition of necroptosis in 
the cuprizone model increased the fraction of myelinated axons, most likely 
protecting oligodendrocytes from demyelination (97); however the role of 
microglial necroptosis was not investigated, and therefore its potential 
beneficial role in remyelination was not determined.  Mining of RNA sequencing 
data from microglia in another EAE study (data not shown) revealed that both 
Ripk3 and	Mlkl expression is prevalent in late stages of the disease (189), 
correlating with when remyelination has been shown to take place in this model 
(18). Although merely correlative, this may suggest that microglial necroptosis 
may be an important factor for remyelination in EAE. On the contrary, 
microglial necroptosis has been suggested to contribute to inflammation-
induced retinal neurodegeneration in the rd1 mouse model and in the NMDA 
model of acute retinal injury (190).  Indeed, inhibition of necroptosis with 
necrostatin-1 attenuated retinal inflammation and prevented degeneration, 
although neuronal necroptosis was not measured; therefore the effects of 
necrostatin-1 on preventing neuronal death as a protective outcome in this 
model cannot be ruled out.  
Findings in this thesis may suggest that for efficient remyelination to take place, 
pro-inflammatory microglia must undergo necroptosis, potentially as a way of 
effectively shutting down inflammation and promoting the activation of pro-
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regenerative microglia supportive of remyelination. Also for the first time, it is 
proposed that necroptosis in the CNS may be of benefit, as blocking microglial 
necroptosis prolongs pro-inflammatory microglial activation for a significantly 
longer time and hinders remyelination experimentally, supported by human 
tissue evidence indicating that necroptosing microglia are present in significant 






I have demonstrated that by blocking microglial necroptosis, remyelination is 
significantly hindered, however a key experiment to provide greater 
translational evidence would be to promote or accelerate microglial necroptosis 
in order to enhance remyelination. Although the LPC model is a reliable model 
of efficient remyelination, a more suitable model for this experiment would be 
one where persistent pro-inflammatory microglial activation is prevalent, as 
well as having a poor remyelination potential in order to observe considerable 
differences. For example, spinal cord injury (SCI) models have poor 
regenerative potential (80,	191), as well as persistent pro-inflammatory 
microglia and macrophages throughout (192), and therefore have the potential 
to show profound differences in microglial activation and regeneration. 
Moreover, remyelination in aged mice following spinal cord demyelination is 
significantly impaired compared to young mice (193) and is associated with 
persistent inflammation in microglia (193,	194) and would therefore also be an 
interesting model to determine if promoting microglial necroptosis could 
accelerate remyelination (although the role of microglial necroptosis in both of 
these models needs to be characterised). The chemotherapeutic agent Shikonin 
has been shown to induce necroptosis of glioma and non-small cell lung cancer 
cells (195,	196)  and would therefore be a potential candidate to promote 
microglial necroptosis, although targeted delivery such as via LNC 
encapsulation may be necessary.  
Although necrostatin-1 LNCs were shown to be relatively microglia-specific (by 
diD LNC co-localisation with IBA-1), there was still a small proportion of diD+ 
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clusters not localised to IBA-1+ cells. Furthermore, with evidence suggesting 
that necrostatin-1 may have off-target effects such as IDO inhibition (186), a 
genetic mouse model may provide a more straightforward inhibition of 
necroptosis. For example, an inducible knockout of Mlkl driven by the Csf1r 
promoter would allow specific timing of necroptosis inhibition, specifically in 
microglia and macrophages. Although inducible Cre models have limitations, 
such as limited recombination efficiency, spontaneous recombination and the 
use of tamoxifen to induce Cre-recombination (which has been shown to 
accelerate remyelination experimentally (197)), it would be interesting to 
investigate if this model is more effective at inhibiting microglial/macrophage 
necroptosis and its effects of remyelination compared to necrostatin-1 LNC 
treatment.  
As high concentrations of LNCs have been shown to be toxic to cells by the des 
Rieux lab, it needs to be ensured that the LNCs in these experiments are not 
causing toxicity, and therefore affecting necroptosis or microglial activation 
alone.  Therefore, administration of empty LNCs at the same 1:100 dilution 
should be carried out with and without LPC to see if there is an increase in 
microglial death or a change in activation compared to LPC alone. This could be 
determined by isolation of microglia at 7dpl when a significant decrease in 
microglia is observed in demyelinated lesions and comparing numbers of 
microglia to LPC alone by flow cytometry, and also by looking at death markers 
by flow cytometry at this time, as well as immunostaining for activation 
markers (such as iNOS, Arg-1, CD68 for example). In the empty LNCs without 
demyelination, there should be no observed loss of microglia and minimal cell 
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death marker-positive microglia, comparable to time-matched mice without 
demyelination. Similarly, one would expect no change in the number of 
activated (CD68+) microglia, or the proportions of iNOS+ and Arg-1+ microglia 
at all time points compared to LPC alone.  
Although I have demonstrated the importance of microglial necroptosis, the 
molecular mechanism driving this process is still unknown. Indeed, TNF-α has 
been shown to induce necroptosis in a multitude of cell types (198‐201), and 
microglia-secreted TNF-α has been shown to induce necroptosis in 
oligodendrocytes (97). Whether microglial TNF-α release causes an autocrine 
response to regulate microglial inflammation remains to be determined. Using 
neutralising antibodies against secreted TNF-α would block its activity and 
could be used to assess the role of secreted TNF-α in driving microglial 
necroptosis. Furthermore, it could be that microglia are more resistant to 
necroptosis in disease models with chronic pro-inflammatory microglial 
responses, and the mechanisms that underpin this would could be explored in 
order to uncover novel therapeutic targets aimed at promoting remyelination. 
This could be assessed by looking in models where chronic pro-inflammatory 
microglial activation occurs, such as in ageing mice after demyelination (8,	193,	
194) or in SCI (192). Firstly, immunostaining with necroptosis markers would 
determine if pro-inflammatory microglia do not undergo necroptosis, or if they 
do but either i) repopulation does not take place or ii) repopulation takes place 
but the inflammatory environment leads to pro-inflammatory microglial 
activation in repopulated microglia. If pro-inflammatory microglia in these 
models do not undergo necroptosis, RNA sequencing of microglia in these 
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models could be conducted and compared to RNA sequencing datasets from 
microglia in the LPC model during peak of pro-inflammatory activation (3 dpl). 
This may highlight differences in activation, phenotypes and death and survival 
pathways for example that could explain why pro-inflammatory microglia in 
some models do not undergo necroptosis.  
The importance of monocyte-derived macrophages in this model needs to be 
determined. Firstly, evidence demonstrates that Ccr2-RFP+ macrophages 
express necroptosis marker RIPK3, however it is uncertain if this represents 
pro-inflammatory activation or necroptosis. Analysis of Ccr2-RFP+ by flow 
cytometry with death markers Annexin-V and 7-AAD would determine if 
macrophages are undergoing cell death in this model. Furthermore, selective 
blocking of macrophage necroptosis by a macrophage-specific Mlkl knockout 
(driven by the	Ccr2 promoter, for example), would determine if macrophage 
necroptosis is necessary for i) microglial necroptosis to take place, ii) for pro-
regenerative microglial activation to take place and iii) for efficient 
remyelination to take place. If a persistent pro-inflammatory macrophage 
activation phenotype occurs in this knockout mouse model, it would be 
interesting to observe how this impacts microglial activation and if they can still 
undergo necroptosis and a transition to a pro-regenerative phenotype, and if 
this is sufficient to drive remyelination. Furthermore, a microglial-specific Mlkl	
knockout (driven by the Tmem119 promoter for example) would also determine 
the importance of microglia death for macrophage infiltration and necroptosis 
in this model. For example, if microglia cannot undergo necroptosis and have a 
persistent pro-inflammatory phenotype, can peripheral macrophages promote 
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remyelination alone? These studies will determine the importance of microglial 
and peripheral macrophage necroptosis in driving remyelination.  
Lastly, the gold standard for detection of remyelination is electron microscopy. 
Although a significant difference in MAG pixel intensity in lesions at 10 dpl 
treated with necrostatin-1 LNCs compared to vehicle was detected, suggesting 
that inhibition of microglial necroptosis prevents efficient remyelination, the 
detection of differences in remyelination would be more convincing with 








Microglia are the resident macrophages of the CNS. Although considered long 
lived cells with low turnover, many studies have now demonstrated how rapidly 
microglia can repopulate the brain after depletion (68‐70,	202,	203). However, 
the roles of microglial death and repopulation are understudied. Indeed, I found 
that pro-inflammatory microglial death by necroptosis plays an important role 
regulating microglial phenotypes during remyelination, but the mechanisms 
that underpin how microglial repopulation takes place are unclear. Here, I show 
that repopulation of microglia takes place rapidly after pro-inflammatory 
microglial necroptosis during remyelination. Lineage tracing revealed that the 
source of microglial repopulation is primarily via the expansion of residual 
Nestin+ microglia and supplemented by the differentiation of Nestin+ cells.  
Furthermore, repopulating (Nestin+) microglia are significantly increased in MS 
lesions with high remyelination potential but not in lesions that fail to 
remyelinate, suggesting the importance of these cells in remyelination. This data 
therefore demonstrates how microglial repopulation can take place outside of 
experimental depletion models, and is a feature of remyelination in a 





Microglia have a low turnover under physiological conditions, both in the mouse 
(1.38% of microglia proliferating (BrdU+ incorporation) and 1.23% of microglia 
undergoing apoptosis at all times (66)),  and in humans (28% of microglia 
turnover per year (204)), a major difference compared to the rapid turnover of 
peripheral macrophages (205). However, in response to experimental depletion 
it has been shown that microglia can rapidly repopulate the CNS, both in the 
embryo and in the adult (68‐70,	202,	203,	206). Whereas monocytes are the 
source of peripheral macrophage replenishment, isolation of microglia from the 
periphery results in the reliance on self-renewal. As a result, the source of 
repopulating microglia after depletion has been hotly debated.  
Although under normal conditions, microglia progenitors originate from the 
yolk sac during embryogenesis, depletion studies have sought to determine if 
additional sources of microglia can arise outside of the yolk sac. Depletion of 
primitive embryonic microglia in the yolk sac at E6.5/ E7.5 with a CSF1R 
inhibitor results in a complete lack of microglia in the developing CNS at E10.5 – 
E14.5 when primitive microglia would normally penetrate the rudimental brain 
(206). However, by E17.5 some Cx3cr1-GFP+ microglia were observed to be in 
the brain, and full repopulation occurred by birth (206), suggesting that 
microglia can arise outside of the yolk sac if this source is depleted, potentially 
via definitive haematopoiesis.  
Microglial depletion studies in the adult CNS revealed how repopulation differs 
from the original seeding in development. Two depletion studies relying on 
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different methods, Cx3cr1-CreERT2;iDTR genetic depletion mouse model (68) 
compared to CSF1R inhibition (69), revealed a role for Nestin+ cells in 
microglial repopulation, albeit with different conclusions. After depletion of 
microglia in the Cx3cr1-CreERT2;iDTR mice with diphtheria toxin, residual 
microglia expressed Nestin, as shown by immunohistochemical IBA-1/Nestin 
co-localisation at 7 days post depletion (68). However, by CSF1R inhibition-
mediated microglial depletion, repopulation was suggested to occur via Nestin+ 
cell differentiation (69); BrdU incorporation in proliferating cells revealed the 
majority of BrdU+ cells prior to repopulation were negative for microglia 
markers such as IBA-1, and mice sacrificed during repopulation showed the 
majority of BrdU+ cells were IBA-1+ suggesting that these cells could have come 
from non-microglial BrdU+ origin (69). Although different sources for 
repopulating microglia may reflect differences in depletion methods, it 
highlights the need for definitive lineage tracing studies. Indeed, a recent study 
sought to uncover the source of repopulating microglia by lineage tracing of 
Nestin+ cells using the Nestin-CreERT2::Ai14 reporter mouse and CSF1R-
mediated microglia depletion (70). Nestin+ cell lineage tracing revealed that 
microglia did not arise from tdTomato(Nestin)+ cells, although the 
recombination efficiency of this reporter was not noted. Furthermore, the 
induction of Cre-recombination before depletion, and not during repopulation, 
could theoretically miss a transient Nestin+ cell population arising during this 
time. Nevertheless, lineage tracing of microglia using Cx3cr1-CreER::Ai14 
reporter mice showed that after repopulation, all IBA-1+ cells were 
tdTomato(Cx3cr1)+ and therefore must have originated from microglia. 
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Although spontaneous recombination was not assessed, a potential issue with 
inducible Cre-recombinase based reporter models, the authors convincingly 
show that microglial self-renewal is most likely the source of repopulating 
microglia in the CSF1R inhibition-mediated depletion model. However, it is 
unclear if this is the case for all methods of microglial depletion in the adult CNS, 
and whether this extends to white matter injury.  
Although microglial depletion studies have highlighted the rapid responsiveness 
of microglia to repopulate the CNS, there is no evidence to show how microglia 
repopulate after microglial death without experimental depletion, such as 
during remyelination. Understanding how repopulation takes place during 
efficient remyelination may uncover potential therapeutic targets aimed at 








To determine if Nestin expression in plays a role in repopulation in the LPC 
model of demyelination and remyelination, in	vivo	focal demyelinated tissue 
from 3, 7 and 10 dpl was stained for Nestin and microglia marker IBA-1. Prior to 
microglial death at 3 dpl (when the peak in iNOS+ microglia occurs), and at 10 
dpl (when the peak of Arg-1+ microglia occurs) (8) there was little Nestin+IBA-
1+ microglia present (Figure 1A, C), as was the case in the sham control (Figure 
1A). However, at 7 dpl, a significant proportion of IBA-1+ microglia expressed 
Nestin (Figure 1A-C). Z-plane orthogonal images were obtained at 7 dpl to show 






Figure	1.	A. In	vivo lesioned corpus callosum (dotted line) at 3, 7 and 10 dpl and a sham 
control stained for Nestin (red) and IBA-1 (green). Scale bar, 50µm. B.	Z-plane 
orthogonal view of 7 dpl lesioned corpus callosum stained for Nestin (red) and IBA-1 
(green) demonstrates co-expression. C. Mean percentage co-localization between IBA-1 
and Nestin staining normalized to total IBA-1 signal ± s.e.m.. *P=0.0219 7 dpl vs 10 dpl 








Although we have observed Nestin expression in microglia during repopulation 
after demyelination, the source of repopulating cell types was still to be 
determined; be it Nestin+ progenitor cells or residual microglia expressing 
Nestin. Therefore, lineage tracing was conducted first on Nestin+ cells to 
determine the proportion of these progenitor cells able to differentiate into 
microglia during repopulation. Slices from Nes-CreERT2;RCL-tdT mice were 
cultured and tdTomato expression was induced in Nestin+ cells by 4-
hydroxytamoxifen (4-OHT) prior to demyelination with LPC (Figure 2A). 
Recombination efficiency was observed by immunostaining for Nestin (Figure 







Figure	2.	A.	Schematic of 4-hydroxytamoxifen (4-OHT) treatment in Nes-CreERT2;RCL-
tdT slices. B. Representative slice from Nes-CreERT2; RCL-tdT mice at 21 DIV with 4-
OHT treatment immunostained with Nestin (green) shows high recombination 












In	vivo lineage tracing of Nestin+ cells was also conducted by giving Nes-
CreERT2;RCL-tdT mice two sub-cutaneous injections of tamoxifen 5-7 days 
prior to lesioning (Figure 3A), followed by perfusion of mice at 3, 7 and 10 days 
post demyelination, dissection of lesioned corpus callosum and analysis of 
Nestin+ cells by flow cytometry. Firstly, viable cells were determined by 
forward and side scatter (FSC-A and SSC-A, respectively), followed by gating of 
viable tdTomato(Nestin)+ cells using DAPI, a DNA binding dye that can only 
enter cells with a compromised cell membrane (indicative of cells undergoing 
cell death). DAPI+ tdTomato+ cells were therefore excluded from the gating. 
tdTomato+ cells were gated based on expression of 103 or greater, as a wild-
type (non-tdTomato+) control was not available. A major disadvantage of gating 
without a negative control is that this population can be overestimated, which 
must be noted.  Lastly, tdTomato(Nestin)+ cells were plotting against myeloid 
cell markers CD11b and CD45 (Figure 3B). Therefore, it could be determined by 
flow cytometry the proportion of tdTomato(Nestin)+ cells that expressed 








Figure	3.	A.	Schematic of tamoxifen treatment in Nes-CreERT2;RCL-tdT mice.  B.	Gating 
strategy for to determine the proportion of tdTomato(Nestin)+ cells that express 





Immunostaining Nes-CreERT2;RCL-tdT ex	vivo slices with IBA-1 revealed a 
significant proportion of IBA-1+ cells expressing tdTomato at 2dpl during 
repopulation (Figure 4A, B). Interestingly, at 7dpl there were very few IBA-1+ 
tdTomato(Nestin)+ cells (Fig. 4A), suggesting the Nestin+ microglial population 
is transient. Furthermore, analysis of tdTomato(Nestin)+ cells from in	vivo 
demyelinated lesions revealed a significant proportion (~20%) of 
tdTomato(Nestin)+ cells expressing microglial/ macrophage markers CD11b 
and CD45 at 7dpl which was maintained at 10dpl (Figure 4C, D). Therefore 
evidence from ex	vivo	and in	vivo lineage tracing of Nestin+ cells reveals a small 
population of Nestin+ cells capable of differentiating into microglia as evident 
by the expression of microglia markers IBA-1, CD11b and CD45, all of which are 
not expressed by Nestin+ cells during homeostasis (0 dpl, Figure 4A). It would 
be important to include sham injected (mechanical injury from the needle only, 
or a PBS (vehicle) loaded needle injection) mice in this study to determine the 
baseline numbers of tdTomato(Nestin)+ cells that express microglia/ 
macrophage markers during these time points, however this was not possible 
during this time with limited mice available, however this should be done in the 
future to definitively determine if Nestin+ cells differentiate into microglia only 
in the context of death and repopulation in disease/ injury models such as the 







Figure	4.	A.	Slices from Nes-CreERT2;RCL-tdT mice at 0, 2 and 7dpl immunostained for 
IBA-1 (green). Scale bar, 20µm.		B.	Proportion of IBA-1+ cells positive and negative for 
tdTomato(Nestin) represented as a percentage of total IBA-1+c cells at 0-2 dpl ± s.e.m.	
*P=0.0154	0 dpl vs 2 dpl (Kruskal-Wallis test, Dunn’s Multiple Comparison post-test). 
N=4 mice per time point.	C.	Representative flow plots to show the proportion of 
tdTomato(Nestin)+ cells that express CD11b and CD45 at 3, 7 and 10dpl. D.	Mean 
numbers of CD11b+ CD45+ tdTomato(Nestin)+ cells at 3, 7 and 10 dpl ±s.e.m.. N=3 
mice per time point. *P=0.0496 (one-way ANOVA, Tukey’s multiple comparison post-





As only small proportion of Nestin+ cells expressed microglia markers during 
repopulation (Figure 4), it was important to determine what proportion of total 
repopulating microglia this population represented. Flow cytometric analysis of 
total microglia revealed that tdTomato(Nestin)+CD11b+CD45lo microglia 
represented only approximately 4% of total microglia at 7dpl (Figure 5A), 
suggesting repopulation is likely to mostly result from expansion of the residual 
microglia pool. To address this, lineage tracing of microglia using Cx3cr1-
CreER;RCL-tdT was carried out in slices, whereby treatment of slices with 4-
OHT induced tdTomato expression specifically in Cx3cr1+ cells (Figure 5B). 
Immunostaining of Cx3cr1-CreER;RCL-tdT slices with IBA-1 revealed that a 
proportion of microglia do not undergo necroptosis after demyelination (Figure 
5C, D), as there were tdTomato(Cx3cr1)+ cells present prior to demyelination (0 
dpl) that were still present by 2 dpl when microglial necroptosis had taken 
place. Furthermore, a significant proportion of tdTomato(Cx3cr1)+ microglia 
express Nestin at 2 dpl (Figure 5C, E). Overall this data shows that some 
microglia evade necroptosis and are the primary contributors to repopulation, 






Figure	5.	A.	Representative flow plots of CD11b+CD45+ microglia plotted against 
tdTomato to determine the proportion of total microglia positive for tdTomato(Nestin) 
at 3, 7 and 10dpl and a sham control. B.	Schematic of 4-OHT treatment in Cx3cr1-
CreER;RCL-tdT slices. C. Slices from Cx3cr1-CreER;RCL-tdT mice at 0 dpl and 2 dpl 
immunostained for IBA-1 (green) and Nestin (magenta). Scale bar, 20µm.		D. 
Proportion of IBA-1+ cells positive and negative for tdTomato(Cx3cr1) represented as a 
percentage of total IBA-1+ cells at 0-2 dpl ± s.e.m.	N=4 mice per time point.	E.	
Proportion of tdTomato(Cx3cr1)+ cells positive and negative for Nestin represented as 
a percentage of total tdTomato(Cx3cr1)+ cells at 0-2 dpl ± s.e.m.	*P=0.0106	0 dpl vs 2 







Super resolution imaging of Nes-CreERT2;RCL-tdT slices was carried out to 
determine if Nestin+ cells truly expressed IBA-1, or if microglia phagocytosis of 
Nestin+ cells was the reason for co-localisation of markers. This revealed 
Nestin+ IBA-1 marker co-localisation (Figure 6A), however in rare cases 
microglial phagocytosis of Nestin+ debris was also observed (Figure 6B).  Single 
labelled controls were not carried out to determine channel bleed-through, 
however areas of IBA-1+ only and tdTomato(Nestin)+ only are observed, 





Figure	6.	A.	Super resolution image of tdTomato(Nestin)+ cell (magenta) expressing 
IBA-1 (green). B.	Example of tdTomato(Nestin)+ cell fragments (magenta) having been 
phagocytosed by IBA-1+ microglia (green; arrow).   
4.3.7.	Nestin+	cells	express	markers	of	neural	stem	cells	but	not	astrocyte	markers		
To understand the identify of the Nestin+ cells with capacity to differentiate into 
microglia, Nes-CreERT2;RCL-tdT slices were immunostained for neural stem cell 
marker mushashi-1 (Msh-1; Figure 7A) and SOX-2 (Figure 7B), as well as 
astrocyte marker glial fibrillary acidic protein (GFAP; Figure 7C) prior to 
demyelination. Immunostaining revealed that tdTomato(Nestin)+ cells 
expressed Msh-1 and Sox-2 but not GFAP, suggesting they may be of neural 
stem cell origin, and not trans-differentiated astrocytes (Figure 7A-C). However, 
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GFAP is a marker of activated astrocytes, therefore a pan astrocyte marker such 
as ALDH1L1 could be used to determine if any tdTomato(Nestin)+ cells express 
pan astrocyte markers.  
 
Figure	7.	A.	Representative image from Nes-CreERT2;RCL-tdT slices immunostained 
for Msh-1 (green). Scale bar, 20μm. B.	Representative image from Nes-CreERT2;RCL-
tdT slices immunostained for SOX-2 (green). Scale bar, 20μm. C.	Representative image 







It has previously been shown that oligodendrocytes can express Cx3cr1 (207). 
Therefore, to determine if oligodendrocytes are contributing to the 
tdTomato(Cx3cr1)+ population, slices from Cx3cr1-CreER;RCL-tdT were 
cultured for 21 days in vitro, fixed and immunostained for oligodendrocyte 
lineage marker Olig2 which revealed that there were no tdTomato(Cx3cr1)+ 
cells expressing Olig2 (Figure 8) prior to demyelination.  Although demyelinated 
slices were not analysed for tdTomato(Cx3cr1)+ Olig2+ cells, there is no 
evidence to suggest that Olig2+ cells upregulate Cx3cr1 in during 
differentiation. Therefore, our lineage tracing using Cx3cr1-CreER;RCL-tdT mice 
is specifically tracing microglia.  
	
Figure	8.		Representative slice from Cx3cr1-CreER; RCL-tdT stained for Olig2 (green) 




To determine if microglial repopulation is a feature of multiple sclerosis lesions, 
post mortem tissue was stained for macrophage marker PU.1 and Nestin. Lesion 
subtypes were explained in Chapter 3 (see results, section 3.3.13). Active lesions 
show significantly increased density of PU.1+Nestin+ cells compared to control 
white matter tissue (Figure 9A-C), suggesting that microglial repopulation may 
be a feature seen in remyelinating lesions. Interestingly, some remyelinated 
lesions had a high density of PU.1+Nestin+ cells, and some lesions had very few. 
This may represent differences in the stage of remyelination of each lesion. It is 
important to note that PU.1 is not microglial specific, and that further analysis 
with a microglia-specific marker such as Tmem119 or P2ry12 could be used 
instead. However, it has been shown that microglia downregulate these 
homeostatic markers when activated (103) and therefore there are limitations 
of using microglia-specific markers in such conditions. Furthermore, our ex	vivo 
evidence of Nestin+ PU.1+ cells suggests that it is microglia that do indeed 
express Nestin (Figure 4, 5), as peripheral cells capable of expressing Nestin 




Figure	9.	A. Control brain and active MS lesion tissue immunostained for PU.1 (blue) 
and Nestin (red), counterstained with Hoechst (turquoise). Scale bar, 20μm.  B. 
Magnified view of a Nestin+ (blue) and PU.1+ (red) cell in an active lesion, 
counterstained with Hoechst (turquoise). C. Mean density of Nestin+ PU.1+ cells per 
mm2 in control, active, chronic inactive and remyelinated lesions. Individual data points 
represent separate lesions (See Results	Chapter	1,	Table	1). *P=0.0329 active lesions vs 
control (Mann-Whitney test). Remyelinated v control p=0.5523; chronic inactive v 




As I showed that microglial necroptosis is important in the regulation of pro-
inflammatory microglia, I next determined how microglial repopulation takes 
place during efficient remyelination. Understanding how microglia repopulate 
may uncover a potential therapeutic target in driving pro-regenerative 
microglial activation in diseases where chronic pro-inflammatory microglial 
activation and failed remyelination feature, including MS and spinal cord injury 
(SCI) (8,	192,	208).  
After pro-inflammatory microglial necroptosis, I found that rapid repopulation 
occurred in both ex	vivo and in	vivo models prior to the onset of remyelination. 
During repopulation, microglia were found to express the neural stem cell 
marker Nestin, and lineage tracing confirmed that a small proportion of 
repopulating microglia are derived from Nestin+ progenitor cells (also 
expressing SOX2 and Msh1). However the primary source of repopulating 
microglia were found to be derived from residual microglia, as shown by lineage 
tracing using Cx3Cr1 (a proportion of which expressed Nestin during this 
repopulation phase). Furthermore, in MS lesions, a significantly higher density 
of PU.1+Nestin+ cells was observed in active lesions compared to white matter 
from controls. Importantly, this research has shown for the first time that 
microglia repopulate during efficient remyelination (without experimental 
microglial depletion), and that this can occur from various sources.  
A recent study was the first to investigate the role of repopulating microglia in a 
model of CNS damage. Depletion of ~90% of pro-inflammatory microglia by a 
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CSF1R inhibitor in a diphtheria toxin model of hippocampal neuronal loss lead 
to repopulation of microglia that were less activated, as shown by 
morphological analysis (more branched and less amoeboid) and a reduction in 
expression of CD68, a marker of activated microglia and macrophages. 
Furthermore, repopulated microglia did not become pro-inflammatory as 
shown by a significant reduction in expression of inflammatory genes and 
pathways including NFκB, TLR4 and IL-1 compared to mice without microglia 
depletion. Importantly, microglial depletion and repopulation in this disease 
model also lead to an increase in synaptic plasticity as shown by increased spine 
number, as well as a rescue of behavioural deficits (202). This work was the first 
to show a beneficial role of depleting pro-inflammatory microglia to shut down 
inflammatory responses in a model of neurodegeneration, and to suggest a 
potential role for repopulating cells in promoting CNS health.  
Microglial repopulation has not always been shown to be beneficial. For 
example, depletion of spinal cord microglia with Mac-1-saporin lead to the 
depletion of 50% of microglia as well as an acute inflammatory response, as 
shown by increases in gene expression of TNF-α, IL-1β, CCR2 and IL-6 in spinal 
cord lysates (203), although it is unclear which cell types are responsible for this 
inflammatory response. In the same study, peripheral nerve injury was induced 
after microglial repopulation occurred to investigate the beneficial effects of 
repopulated microglia on regeneration. However, microglial depletion and 
repopulation prior to injury resulted in a lack of beneficial responses (such as 
no differences in pain perception). As spinal cord injury models are associated 
with chronic pro-inflammatory microglial responses (192), depletion of 
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microglia during the peak of pro-inflammatory microglial activation may have 
been a more physiologically relevant experiment. Therefore, it is uncertain if 
depletion and repopulation of microglia after injury would benefit peripheral 
nerve regeneration in the spinal cord (203). Furthermore, differences in CNS 
regions, methods of depletion and level of depletion achieved may account for 
differences in repopulation and regenerative benefits, and therefore such 
differences and their impacts on microglia repopulation and activation need to 
be elucidated.  
There is evidence demonstrating how microglia are able to express markers of 
other cell types in response to activation and injury. For example, microglia 
have been shown to express markers of haematopoietic stem cells such as CD34 
(209) and c-kit (210) in response to neuronal injury in	vivo. Primary microglial 
cultures treated with IFN-γ can also express neural lineage markers β-III 
tubulin, doublecortin (DCX) and Nestin (79). However, mature neuronal 
markers such as NeuN, NF-H and MAP2 were not expressed by IFN-γ treated 
microglia. Furthermore, mature myelin marker MBP was not expressed in IL-4 
treated microglia despite an increase in oligodendrocyte lineage marker NG2 
expression. Therefore, activated microglia do not express mature cell markers 
of other cell types, suggesting that microglia express progenitor markers in 
response to activation rather than microglia undergoing trans-differentiation in 
response to injury/ activation.  
Classically, Nestin expression is associated with neural stem cells (NSCs), 
expressed by mitotically active NSCs in neurogenic niches like the hippocampus 
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(211), and is downregulated in mature neurons (212). Nestin is an intermediate 
filament, and represents a major structural protein in the cytoskeleton (213), 
having an important role in structural organisation and reorganisation of cells, 
particularly in progenitor cells (214). Nestin expression may also be associated 
with activated cells requiring a degree of plasticity, such as in mature neurons 
and astrocytes during glial scar formation after spinal cord injury (215), and 
therefore is not solely a marker of neural stem cells in the CNS. Nestin 
expression in microglia has been studied for the last decade, although little is 
definitively known about its role in microglial activation or repopulation. 
Indeed, Nestin expression may be important for cytoskeleton rearrangement in 
proliferating microglia, although it is uncertain yet if Nestin is essential for 
proliferating microglia during repopulation in my models (see	future	directions). 
tdTomato(Nestin)+ cells from ex	vivo cultures express additional neural stem 
cell markers Msh-1 and SOX2, suggesting these cells may be neural stem cells, 
however further analysis of these cells by gene expression profiling will aid in 
identifying their identity, and if all Nestin+ cells have the potential to 
differentiate into microglia.  
In the adult rat cerebral cortex it has been reported that ~20% IBA-1+CD11b+ 
microglia also express Nestin under normal conditions, and of these Nestin+ 
microglia, the majority also express the astrocyte marker vimentin, and NG2 
(216). However, it is now appreciated that a proportion of microglia turn over at 
any given time (66,	204) and therefore this subpopulation of microglia 
expressing intermediate filament and progenitor cell markers may represent 
microglia actively turning over. Although Nestin+IBA-1+ microglia were only 
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observed in demyelinated lesions and not in sham lesions or outside of the 
lesion area in our model (Figure 1A), the discrepancy with the previous study 
could also represent regional differences in microglial activation and rates of 
turnover (1,	66,	147,	217). Indeed, as much as 60% of microglia in the retina 
express Nestin under normal conditions, which increases in response to optic 
nerve transection (218). Furthermore, microglia positive for Nestin and 
Bromodeoxyuridine (BrdU), a synthetic analogue of thymidine incorporated 
into actively proliferating cells, significantly increased in response to injury 
leading to an expansion of Nestin+ microglia (218), suggesting a role of Nestin in 
the proliferation of microglia. Moreover, evidence from this thesis suggests that 
Nestin expression in microglia may represent proliferation after injury, 
specifically due to pro-inflammatory microglial death, and therefore as a 
repopulation mechanism, which may represent a previously unappreciated role 
for microglial proliferation after injury. However, microglial proliferation 
(identified by Ki67 expression or BrdU incorporation, for example) was not 
directly measured, and will need to be carried out in order to confidently assess 
proliferation in repopulating microglia (see future	directions).  
Nestin expression has also been shown to be an indicator of astrocyte activation 
in response to mechanical injury of the mouse hippocampus (219), as well as 
being associated with microglial activation in	vitro (220) and in	vivo (218). 
However, at the peak of iNOS+ microglial activation there were significantly 
fewer Nestin+ microglia compared to during repopulation (7 dpl in	vivo;	Figure 
1A, C), suggesting that Nestin expression in microglia is associated with 
repopulation rather than solely microglial activation.  
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My lineage tracing results revealed that although residual microglia represent 
the major source of repopulating microglia, there is a small population of 
Nestin+ cells capable of differentiating into microglia (Figure 4C, D). Although 
repopulation via Nestin+ progenitors has been reported previously after 
microglial depletion in the mouse CNS (69), it is unclear why both residual 
microglia and Nestin+ cells would contribute to repopulation. It may be that 
regional differences, depletion methods, mechanism of cell death and extent of 
microglial depletion may result in differences in repopulation mechanisms, 
although this need to be thoroughly explored before any conclusions can be 
made. Furthermore, differences in methods of progenitor cell detection and 
their sensitivities (such as reporter cell lineage tracing compared to fate 
mapping with BrdU, for example) may also lead to differences in findings. 
Indeed, incomplete recombination or spontaneous recombination with 
inducible-Cre driven reporter mice may conceivably lead to under- or over-
representation of a particular population, respectively, and therefore both 
recombination efficiency and levels of spontaneous recombination should be 
assessed.  
It is unclear if all Nestin+ cells are capable of differentiating into microglia, as 
only a proportion of tdTomato(Nestin)+ cells expressed IBA-1 during 
repopulation (Figure 4) and therefore there may be a degree of heterogeneity in 
Nestin+ cells. Moreover, the signals that drive a Nestin+ progenitor cell to 
differentiate into a microglia remain unknown, and it is unclear if Nestin+ cell-
derived microglia permanently reside in the CNS after repopulation. Microglia 
repopulation may take place in response to signals from dying cells, and could 
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potentially lead to differences in repopulation sources based on how the 
microglia died (by apoptosis or necroptosis for example). Alternatively, 
microglia repopulation studies have shown that initially excess microglial 
proliferation occurs and is followed by a decrease in microglia to levels similar 
to pre-depletion levels (68). This suggests that repopulation may be in response 
to detectable changes in microglial numbers, either by residual microglia 
and/or Nestin+ cells. Lineage tracing of tdTomato(Nestin) slices after 
repopulation has taken place in	vivo (7dpl) revealed that very few 
tdTomato(Nestin)+ IBA-1+ cells are present (Figure 4A). As tdTomato 
expression will persist in cells even if these cells no longer express Nestin, one 
would expect to see tdTomato+ microglia after repopulation if these cells 
persist, however my preliminary findings suggest that this population is 
transient. It is unclear why a small proportion of Nestin+ cells would 
differentiate into microglia, to then die days later. This may represent a 
microglial repopulation overcompensation mechanism, where excess microglia 
undergo death, however the half-life of tdTomato will also need to be 
investigated in order to determine if this population is truly lost after 
repopulation. 
The role of monocyte-derived macrophages (MDMs) during microglial 
repopulation has not been fully addressed. Indeed, microglial depletion via 
CSF1R inhibition does not alter BBB integrity as shown by Evans Blue staining 
(69), although not all depletion studies report BBB integrity. Disruption of BBB 
integrity has been shown to lead to peripheral monocyte invasion of the CNS 
that can contribute to the microglial pool in irradiated mice by bone marrow 
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adoptive transfer (68,	217). Furthermore, recent experimental evidence using 
an inducible knockout of Csf1r in Cx3cr1+ cells (leading to 25% depletion of 
microglia in the CNS) reported that adoptive transfer of GFP+ bone marrow 
derived macrophages leads to  their invasion of the CNS after microglial 
depletion, despite an intact BBB (221).  Interestingly, bone marrow-derived 
monocytes in the CNS can also express Nestin (68) which begs the question: 
what is the contribution of MDMs to microglial repopulation during efficient 
remyelination? Although microglial repopulation in the ex	vivo model occurs 
devoid of peripheral cell contributions, in	vivo demyelination of Ccr2RFP/+ 
reporter mice leads to a small population of RFP+ MDMs in the lesion (See 
Chapter	3); however I have not yet uncovered whether these cells express 
Nestin during remyelination or contribute to microglial repopulation in the 
long-term (see future	directions).  
Lastly, although Nestin+PU.1+ cells are observed in MS lesions with high 
capacity for remyelination (active lesions), it is unclear if these cells represent 
Nestin+ cells which have differentiated into microglia, or microglial expression 
of Nestin. Nestin expression in activated astrocytes in the formation of glial 
scars in MS lesions has been reported previously (222,	223), but evidence for 
the role of microglial Nestin expression in MS is lacking. Furthermore, my 
observation of a decrease in Nestin+PU.1+ cells in lesions with limited 
remyelination capacity (chronic inactive) could represent a block in 
repopulation, or a consequence of a lack of pro-inflammatory microglial 
necroptosis (See Results	Chapter	1). Therefore, there is still a great deal of 
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information regarding the role of Nestin expression in microglia in the human 
context that needs to be uncovered.  
Taken together, I present evidence to show that microglia repopulate after pro-
inflammatory necroptosis during efficient remyelination. Lineage tracing of 
Nestin+ cells and microglia reveals that the majority of repopulation originates 
from residual microglia, with a small contribution of Nestin+ cells 
differentiating into microglia. Lastly, active MS lesions were associated with 
Nestin+ microglia, whereas other lesion types have significantly fewer Nestin+ 
microglia. Given that active lesions are associated with higher macrophage 
infiltration and a greater potential for remyelination (163), this could suggest 
that repopulating microglia may be important in remyelination in the human 





There are a few key experiments needed to definitively show the importance of 
repopulating microglia in regulating microglial phenotypes and remyelination. 
Firstly, although it is suggested that repopulating microglia represent the pro-
regenerative microglial population based on the timing of repopulation during 
efficient remyelination, lineage tracing of repopulating microglia and 
immunostaining of these cells with pro-regenerative markers (such as Arg-1 
and CD206) would definitively show if repopulating microglia become pro-
regenerative. Furthermore, by knocking out Nestin, it would be interesting to 
see if repopulation takes place, firstly to determine if Nestin+ cells are needed 
for repopulation, and if microglia need to express Nestin to proliferate and 
repopulate the lesion. As Nestin is vital for neural stem cell development (224) a 
microglial-specific, inducible knockout (K/O) may be the most suitable 
transgenic K/O mouse to use in this circumstance, as this would determine the 
role of Nestin specifically in microglia during microglial repopulation. On that 
matter, it would be important to determine if microglial proliferation is an 
important driver of microglial repopulation, or whether microglia from outside 
of the lesion site are able to migrate into the lesion site to assist with 
repopulation. The use of microfetti mice (225) would be able to determine if 
repopulation occurs inside of the lesion by expansion of residual microglia in 
close proximity. This may be more realistic than tracking microglia outside of 
the lesion, which may be possible using in	vivo live imaging (which has 
limitations on size of area able to be observed, resolution of deep brain 
structures, and length of time able to track microglia (which may be days)).  
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Although I have shown that by blocking microglial necroptosis there is a 
persistence in iNOS+ microglial activation, it would be interesting to see if 
repopulation is also blocked as result. Although this may seem like a logical 
consequence of preventing microglial death, it would also rule out a role of LPC 
or demyelination in promoting microglial proliferation or Nestin expression, 
independent of microglial numbers.  
As mentioned in the discussion, it is unclear if peripheral macrophages 
contribute to microglial repopulation during efficient remyelination. Lineage 
tracing of macrophages using Ccr2RFP/+reporter mice would address this. Firstly, 
immunostaining for Nestin would determine if MDMs express Nestin in the 
demyelinating lesions, and for how long. Furthermore, imaging lesion areas 
after remyelination is complete for RFP+ cells would show how long MDMs 
persist in the brain; whether they exit after inflammation subsides and 
remyelination is complete, or whether they stay in the brain and contribute to 
the microglial population. Furthermore, staining for microglial-specific markers 
TMEM119 and P2RY12 (103) could potentially show if MDMs adopt microglial 
markers once in the brain, and therefore contribute to the microglial population.  
In light of evidence showing regional differences in microglial gene expression 
(147) and suggestions that microglia in some regions of the brain can express 
Nestin under homeostatic conditions (216,	218), it would be interesting to see if 
there are regional differences in microglial repopulation during remyelination, 
and if there are differences in microglial repopulation/ remyelination efficiency 
in grey matter compared to white matter. This could be done by similar lineage 
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tracing and immunostaining techniques as used in our ex	vivo and in	vivo 
models, but in different areas of the brain.  
Lastly, the identity of these Nestin+ cells capable of microglial differentiation is 
still uncertain. Indeed, if only a subset of Nestin+ cells are capable of 
differentiation into microglia, it would be important to know differences in 
these cells compared to other Nestin+ cells, and whether or not Nestin+ neural 
stem cells can indeed differentiate into microglia. By FACS sorting out 
tdTomato(Nestin)+ cells at different stages during remyelination (un-
demyelinated corpus callosum, during demyelination, during repopulation and 
after repopulation) for RNA-sequencing and comparing tdTomato(Nestin)+-
CD45- cells to tdTomato(Nestin)+CD11b+CD45+ Nestin+ cell-derived microglia, 
and to tdTomato(Nestin)-CD11b+CD45+ microglia, I could uncover key 








During remyelination, microglia switch their phenotype from pro-inflammatory 
to pro-regenerative and failure of this switch leads to a sustained pro-
inflammatory response and poor remyelination, associated with diseases like 
multiple sclerosis (MS). Therefore, targeting microglia to promote a pro-
regenerative phenotype may be of therapeutic value. Here, we screened 
immunomodulatory compounds known to have regenerative properties in	vivo 
(136,	140,	144,	145) in an attempt to promote a pro-repair phenotype in primary 
rat microglia. Co-treatment of primary rat microglia cultures with 4 known 
immunomodulatory compounds and LPS and IFN-γ reduced microglial TNF-α 
secretions compared to LPS and IFN-γ treatment alone, although further 
analysis by immunostaining revealed an accelerated reduction of pro-
inflammatory microglia compared to IFN-γ/LPS treatment alone. This 
correlated with an inhibition of NFκB activation, suggesting that 
immunomodulation may be taking place through inhibition of pro-survival 
NFκB signalling leading to cell death of the microglia, rather than an immune-
resolution or switch in phenotype. Therefore I reveal a previously 
unappreciated mechanism of immunomodulation distinct from the conventional 
idea of dampening activation, and may represent a novel therapeutic strategy 





Microglia are highly dynamic, able to alter their genetic, phenotypic and 
functional behaviours in response to changes in their microenvironment. A 
prime example of this is during remyelination, where microglia firstly activate 
to become pro-inflammatory in phenotype in response to demyelination, then at 
the initiation of remyelination, microglia change their phenotype to an anti-
inflammatory/ pro-regenerative in phenotype (8).  
My data in Chapters 3 and 4 of this thesis demonstrate that during efficient 
remyelination, pro-inflammatory microglia undergo necroptosis leading to 
repopulation of microglia prior to the peak in pro-regenerative microglial 
activation that initiates remyelination (8). Furthermore, I had observed that in 
MS tissue, active lesions that can undergo remyelination had significant levels of 
necroptotic (RIPK3+ MLKL+ CD68+) and repopulating (Nestin+ PU.1+) 
microglia compared to white matter control tissue (see	Chapter	3	and	4), 
suggesting that a block in microglial death and /or repopulation may contribute 
to the persistent pro-inflammatory phenotype in lesions that fail to remyelinate. 
Although microglial death may not regulate phenotypic changes in all models, 
this work highlighted a potential novel therapeutic avenue of targeting pro-
inflammatory microglial death in order to promote faster repopulating and 
remyelination.  
One potential molecular candidate involved in regulating macrophage activation 
and survival is the transcription factor NFκB, associated with susceptibility for 
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Multiple Sclerosis (MS) (130,	131,	133,	226). Indeed, compounds that modulate 
macrophage activation and inflammation in EAE and spinal cord injury models, 
including 17-β Estradiol (143), substance P (140), PPARγ agonists (227) and 
Rho kinase inhibitors (138) also have converging downstream mechanisms of 
action through inhibiting the function of NFκB (141,	228‐230). For example, 17-
β Estradiol pretreatment of microglia prevents LPS-induced translocation of the 
P65 subunit of NFκB by directly interfering with transport microtubules that 
guide the NFκB subunit to the nucleus (141) as well as having indirect effects on 
NFκB via interacting with PPARγ (231), a transcription factor that may act by 
promoting its ubiquitination and degradation (232). Furthermore, Rho kinase 
inhibition prevents proliferation, survival and cell contractility via inhibition of  
NFκB activation and translocation into the nucleus (228). Lastly, the role of 
substance P in attenuating inflammation remains controversial; there is in	vivo 
evidence that substance P treatment ameliorates severity of disability and 
promotes anti-inflammatory macrophage activation in a model of spinal cord 
injury in mice (140). However, in	vitro work has shown that substance P can 
promote NFκB activation (229), suggesting that substance P may drive 
immunomodulation via an NFκB-independent manner.  
Altogether, evidence suggests that manipulation of microglia/ macrophages by 
manipulation of the NFκB pathway can lead to anti-inflammatory activation, 
here I asked whether use of such compounds could affect pro-inflammatory 








Primary microglia were first polarised to a pro-inflammatory phenotype in	vitro 
by standard treatment with IFN-γ and LPS, as done previously (8). Microglia 
rapidly activated to a pro-inflammatory phenotype, as indicated by iNOS 
expression and loss of anti-inflammatory associated marker mannose receptor 
expression at 8 hours post-treatment (Figure 1A-D) and production of TNF-α 
(Figure 1F). Interestingly, a significant loss of microglia (quantified as number 
of cells per field) treated with IFN-γ/LPS began at 16 hours post-treatment 
(Figure 1E) relative to an untreated, time-matched control, such that by 24 
hours very few microglia remained. Untreated microglial numbers remained 
constant throughout, therefore loss of microglia in IFN-γ/LPS treated microglia 






Figure	1.	A‐D.	Microglia stained for iNOS (green) and mannose receptor (red) at 2, 8, 
16 and 30 hours post IFN-γ/LPS treatment. Scale bar, 25µm. E. Microglia cell count over 
30 hours post IFN-γ/LPS treatment (red line) and time matched untreated controls 
(blue line) ±s.e.m.. *P<0.05, **P<0.01, ***P<0.001 (Mann-Whitney test, IFN-γ/LPS v 
control). N=3 biological repeats. F. Concentration of secreted TNF-α from IFN-γ/LPS 
treated microglial conditioned media at 2-10 hours post treatment compared to time-
matched untreated controls ±s.e.m.. *P<0.05 (Mann-Whitney test). N=3 biological 





Screening of 4 different compounds with immunomodulatory properties in 
models of CNS injury (17-β Estradiol, Substance P, Rho kinase inhibitor HA-
1077 and PPAR-γ agonist Rosiglitazone) (140,	144,	145,	227) was carried out to 
determine if pro-inflammatory microglia death is accellerated. Concentrations 
for each compound were chosen based on previous in	vitro experiments, 
although a wide range of concentrations have been used in the literature, and 
therefore a broader range of concentrations were also used here. 5 
concentrations of each compound and their respective vehicle controls (ethanol 
(17b-estradiol), DMSO (Rosiglitzone and HA-1077) and PBS (substance P)) 
were used to treat microglia at the time of polarisation with IFN-γ/LPS. Analysis 
of conditioned media collected from treated cultures prior to cell loss in IFN-
γ/LPS condition  (10 hours post treatment) revealed a significant decrease in 
TNF-α production with 3 of the 4 compounds with at least one concentration 
compared to vehicle control (Figure 2A). Concomitantly, all compounds showed 
an increase in IGF-1 production with at least one concentration (Figure 2B). 
However, this decrease in TNF-α levels may have reflected microglial loss, as 
analysis of microglia numbers revealed an accelerated decrease with each 
compound compared to IFN-γ/LPS + vehicle (Figure 2C-F). Interestingly, the 
highest dose of 17-β Estradiol significantly increased TNF-α production (Figure 
2A) which may reflect polarising differences in immune responses in low dose 





Figure	2.	A.	Mean concentration of TNF-α in conditioned media of pro-inflammatory 
microglia co-treated with 17-β Estradiol, Substance P, HA-1077 and Rosiglitazone at 10 
hours post treatment ±s.e.m.. *P<0.05, **P<0.01, ***P<0.001 (Mann-Whitney test 
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compared to vehicle). N=3 biological repeats. B. Mean concentration of IGF-1 in 
conditioned media of pro-inflammatory microglia co-treated with 17-β Estradiol, 
Substance P, HA-1077 and Rosiglitazone at 10 hours post treatment. N=3 biological 
repeats. C‐F. Mean microglia numbers at 10 hours post IFN-γ/LPS treatment alone or 
co-treated with vehicle control or immunomodulatory compound at concentrations 






As each immunomodulatory compound accelerated microglia cell loss and have 
been shown to regulate the activation of the pro-survival factor NFκB, their 
effects on NFκB activity in pro-inflammatory microglia were investigated. When 
activated, NFκB subunit P65 translocates to the nucleus and binds to NFκB DNA 
binding sites to initiate transcription (235). Therefore, nuclear P65 can be used 
as a readout of NFκB activity. For this, microglia were treated with IFN-γ/LPS 
for 1 hour prior to fixation and immunostaining with P65 and counterstained 
with the actin cytoskeleton dye phalloidin to visualise the whole cell membrane, 
and Hoechst to visualise the nucleus (Figure 3A, B). Image analysis quantified 
the nuclear pixel intensity of P65 with Image J software (indicative of nuclear 
translocation and therefore NFκB activity) in microglia treated with IFN-γ/LPS, 
IL-4, IL-13 or combinations of each to identify basal levels of P65 nuclear co-
localisation in pro-inflammatory microglia (IFN-γ/LPS) compared to pro-
regenerative microglia (IL-13, IL-4) (Figure 3C). Nuclear pixel intensity was 
measured as a mean of the whole nucleus, and then recorded as nuclear pixel 
intensity relative to IFN-γ/LPS treated microglia (used as a positive control). IL-
13 and IL-4 are used classically to induce an anti-inflammatory microglial 
phenotypes (8,	220), and were therefore used as the negative controls. 
Untreated cultures exhibited around 40% lower P65 nuclear co-localisation 
compared to IFN-γ/LPS treated cultures, as did IL-4 and IL-13 treated cultures 
(Figure 3C). Furthermore, IFN-γ/LPS treated microglia co-treated with IL-4 and 
IL-13 also showed decreased P65 nuclear co-localisation, suggesting that potent 
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immunomodulation can be visualised by inhibition of P65 translocation. 
Although baseline nuclear NFκB levels were relatively high in untreated 
cultures, there was enough of a distinction between baseline and IFN-γ/LPS-
treated microglia to use this assay to investigate the effect of our candidate 





Figure	3.	A.	Immunostaining of untreated microglial cultures with NFκB subunit P65 
(green), with cytoplasm stained using phalloidin (red). Scale bar, 25µm. B.	
Immunostaining of IFN-γ/LPS microglial cultures with NFκB subunit P65 (green), with 
cytoplasm stained using phalloidin (red). Scale bar, 25µm. C. Nuclear pixel intensity of 
P65 staining in untreated microglia or microglia treated with IFN-γ/LPS, IL-13, IL-4 or 
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A smaller range of concentrations of each compound were chosen based on 
those most effective at inhibiting TNF-α production in microglia co-treated with 
IFN- γ/LPS. Co-treatment of IFN-γ/LPS treated microglia with 
immunomodulatory compounds lead to a significant reduction in NFκB P65 
nuclear translocation indicated by pixel intensity in 3 of the 4 compounds 
(Figure 4A-D). However, as rosiglitazone does not inhibit nuclear translocation 
of NFκB, rather it binds to the P65 subunit preventing binding to DNA binding 









Figure	4.	A‐D.	Mean NFκB P65 nuclear pixel intensity in pro-inflammatory microglial 
cultures co-treated with 17-β Estradiol, Substance P, HA-1077 and Rosiglitazone 
±s.e.m.. *P<0.05, **P<0.01, ***P<0.001 (Mann-Whitney test compared to vehicle). N=3 









Effective therapies that attenuate inflammation and promote remyelination are 
currently lacking, yet this represents a promising therapeutic strategy for 
diseases like progressive MS. A potential cellular target for such a therapy is the 
microglia, as a switch in activation from pro-inflammatory to pro-regenerative 
phenotypes is essential for remyelination to take place (8). I investigated four 
compounds known to have immunomodulatory properties and promote repair 
in various experimental models of CNS injury (136,	138,	140,	236). Using an 
established in	vitro method of inducing pro-inflammatory activation in 
microglia (IFN-γ/LPS), I set out to investigate if these compounds can directly 
influence the activation properties of microglia, either by inducing cell death or 
by promoting a pro-repair phenotype.  
Co-treatment of compounds with IFN-γ/LPS showed significant decreases in the 
production of TNF-α compared to IFN-γ/LPS alone. Known to further potentiate 
the inflammatory response (237,	238), microglial-derived TNF-α has also been 
shown to induce death of hippocampal neural progenitor cells in	vitro (239), as 
well as oligodendrocytes in EAE and MS (97), therefore indicating one way in 
which chronic pro-inflammatory microglial activation can be detrimental for 
neural health. Interestingly, at least one concentration of each compound caused 
an accelerated loss of microglia, suggesting that decreases in TNF-α may be due 
to less pro-inflammatory microglia being present, and inducing microglial death 
may represent a novel mechanism for immunomodulation. 3 out of 4 
compounds also significantly inhibited NFκB nuclear translocation 
representative of activation, suggesting a role of NFκB in microglial 
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inflammation and survival, and may represent a novel therapeutic avenue in 
pro-inflammatory microglial immunomodulation.  
I now have evidence suggesting that pro-inflammatory microglial undergo cell 
death in another model in	vitro,	although definitive proof of cell death (by 
propidium iodide incorporation, for example) is needed before we can fully 
conclude this. Furthermore, microglia underwent cell death 8 hours earlier 
when co-treated with each of the 4 immunomodulatory compounds (Figure 2C-
F), suggesting that these compounds can accelerate pro-inflammatory microglial 
death. Although microglial death leads to repopulation in	vivo (68‐70,	202,	203), 
and repopulation may support a pro-regenerative microglial phenotype (202), it 
is most likely that our	in	vitro	experimental set up will be unable to investigate 
the effects of these compounds on promoting a pro-regenerative microglial 
phenotype. Although, in	vitro repopulation has not been assessed; indeed 
microglia that do not die after treatment may be able to repopulate the cultures 
and become pro-regenerative, which could be explored, yet microglial 
proliferation in	vitro takes place regardless of microglial numbers and may be 
too far removed from the in	vivo environment for any relevance. However, given 
my evidence for microglial necroptosis being important for remyelination (see	
Chapter	3) and selective depletion of microglia in the adult mouse leading to 
rapid repopulation (68‐70,	202,	203), promoting pro-inflammatory microglial 
death therapeutically may be of benefit for disorders where chronic pro-
inflammatory microglial activation occurs, such as in MS (8,	240‐242), ageing 
(91,	147) and spinal cord injury (192,	208,	243,	244). Therefore, I focused on the 
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molecular mechanisms that underpin the accelerated cell death caused by these 
compounds on pro-inflammatory microglia.  
NFκB activation is vital for the initiation and potentiation of inflammatory 
responses in macrophages and microglia (235,	245) as well as being a potent 
pro-survival mediator (246). For these reasons I investigated the effect the 
compounds on inhibiting NFκB activation in pro-inflammatory microglia. This 
family of transcription factors comprised of 5 subunits; RelA (p65), Rel B, c-Rel, 
p50 and p52, are ubiquitous to most cells in mammals and are involved in a 
wide range of responses including survival, proliferation, differentiation and 
inflammation. The canonical pathway activated by most NFκB-stimuli is the 
most extensively studied, induced by activation of tumour necrosis factor alpha 
receptor (TNFR1), interleukin-1 receptor (IL-1R), and pattern-recognition 
receptors (e.g. toll-like receptor 4 (TLR-4)) (235). When inactive, subunits in the 
canonical pathway are sequestered in the cytoplasm by inhibitory IκB proteins. 
However, upon stimulation, IκB proteins are phosphorylated by the IκB kinase 
(IKK) complex (made up of IKKα and IKKβ, and regulatory subunit NEMO), 
which leads to ubiquitination and subsequent proteasomal degradation of the 
inhibitory IκB complex, freeing the NFκB subunits (primarily p65 and p50 
subunits) to translocate to the nucleus and initiate transcription (see Diagram	
5). Although NFκB is active in most cell types, its inducible activation has been 







Diagram	5. Schematic representation of the canonical NFκB pathway. Inhibitory IκBα 
sequesters NFκB subunits in the cytoplasm until a stimulus promotes IκBa 
ubiquitination and degradation, allowing nuclear translocation of NFκB proteins. NFκB 









Dysregulation of NFκB has been implicated in a wide range of diseases, more 
recently in autoimmune diseases such as MS. In EAE, high levels of NFκB have 
been detected in the spinal cord, the primary area of demyelination in this 
model (247). Additionally, CNS-specific IKK2 and NEMO knockout mice 
subjected to EAE have ameliorated clinical scores and reduced expression of 
pro-inflammatory cytokines (248). In post mortem MS brain tissue, NFκB is 
localized to glial cells and macrophages near lesions (133), although it is 
uncertain if NFκB activity in macrophages and microglia has been shown to 
differ in lesions with differing levels of remyelination potential. Furthermore, 
genetic screening of blood samples from MS patients showed genes involved in 
the inhibition of NFκB activity were altered in MS patients, which were also 
shown to increase susceptibility for the disease (130). In addition, a genome-
wide association study (GWAS) identified a polymorphism in the TNFRSF1A 
locus which encodes TNF-α receptor 1 (TNFR1) and Mucosa-associated 
lymphoid tissue lymphoma translocation protein 1(MALT1) as an MS 
susceptibility loci (131,	226). This polymorphism has been shown to affect the 
function of TNFR1 (249), known to be an upstream activator of the NFκB 
pathway, and is therefore a possible mechanism by which this polymorphism 
contributes to the pathogenesis of the disease. Inhibition of NFκB activity may 
therefore be a promising target in modulating microglial inflammation, and 
potentially in driving a pro-regenerative phenotype. 
At least one concentration in 3 of the immunomodulatory compounds used in 
this study significantly inhibited NFκB nuclear translocation compared to IFN-
γ/LPS alone at 1 hour post treatment (Figure 4A-C). The PPAR-γ agonist 
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Rosiglitazone does not inhibit NFκB nuclear translocation, but rather directly 
binds to the NFκB binding sites on DNA to inhibit activity (127) and indeed 
there were no significant changes in NFκB nuclear translocation compared to 
vehicle (Figure 4D). Although Rosiglitazone therefore serves as a negative 
control here, it represents a major limitation of this assay in detecting 
reductions in NFκB activity; the assay is only suitable for compounds that 
prevent NFκB translocation. Therefore, a more suitable readout would most 
likely be the expression of proteins associated with inflammation downstream 
of NFκB activation such as IL-2 (250,	251), IL-6 (252,	253) or TNF-α (254,	255).  
Although the loss of microglia began at 16 hours post IFN-γ/LPS treatment, 
translocation of P65 occurred rapidly (within 1 hour), presumably to initiate 
transcription of inflammatory mediators in response to the pro-inflammatory 
stimulation. Without NFκB inhibition, IFN-γ/LPS-treated microglia still 
underwent cell death, albeit later, which may be explained by the high 
concentration of TNF-α produced by the microglia that may indeed cause their 
own death in culture (97,	256). Although my evidence suggests pro-
inflammatory microglia undergo necroptosis in ex	vivo and in	vivo environments 
(see	Chapter	3), it is unclear if microglial TNF-α is the direct cause, and would 
need to be investigated further to determine if TNF-α is indeed the initiator of 
pro-inflammatory microglial necroptosis.  
In conclusion, I have shown in some preliminary in	vitro studies that by 
inhibiting NFκB activity, pro-inflammatory microglia are susceptible to an 
accelerated cell death, which may be a novel and beneficial therapeutic strategy 
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for promoting microglial phenotypic switching, and consequently, 
remyelination. Furthermore, for the first time I suggest that immunomodulation 
can involve inducing death of pro-inflammatory microglia to rapidly shut down 





Although preliminary, I have evidence that immunomodulatory compounds can 
accelerate pro-inflammatory microglial loss which may provide rapid resolution 
of inflammation in disease contexts. Firstly, an important immediate experiment 
would be to show that microglia are indeed dying in	vitro after IFN-γ/LPS and 
this is accelerated with the immunomodulatory compounds, and not just a loss 
of cellular adhesion (if microglia were just losing adhesion, they would be 
washed away during fixation and washing). A propidium iodide assay would 
address this; propidium iodide could be supplemented into microglial media 1 
hour prior to fixation, and the number of PI+ microglia could be quantified over 
time post-IFN-γ/LPS + compound treatment and compared to time-matched 
untreated/ vehicle treated and IFN-γ/LPS + vehicle treated microglial cultures. 
To follow on, screening compounds in an ex	vivo	model of remyelination would 
allow me to look at the effect of these compounds on pro-inflammatory 
microglial death, microglial repopulation and inflammation, as well as 
remyelination. Furthermore, initial experiments in an ex	vivo model would allow 
for rapid screening of many compounds and concentrations before taking this 
into an in	vivo model.  
The LPC model has the advantage of being able to study remyelination without 
concurrent demyelination. However, one challenge is it may be difficult to 
detect significant improvements in remyelination in a model where this process 
occurs so efficiently. Therefore, a model of poor regeneration such as in spinal 
cord injury (192), or in aged mice where pro-inflammatory microglial activation 
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does not resolve (193) may be a more efficient model to look at the effects of 
pro-inflammatory microglial death on regeneration.  
The importance of NFκB activation in the LPC model has not been investigated. 
A microglial-specific constitutively active NFκB transgenic mouse line could be 
used to investigate if altering NFκB expression in microglia alters their 
activation phenotype and, consequently, remyelination. This would also address 
the importance of NFκB activation for microglial survival; do pro-inflammatory 
microglia still undergo necroptosis in this model if NFκB is constitutively active? 
If not, then NFκB activity must be important in the survival of pro-inflammatory 
microglia. Furthermore, in mice with microglia-specific constitutively active 
NFκB, is remyelination hindered? If this is the case, then using 
immunomodulatory compounds that are capable of modulating NFκB activity 
would be interesting to use in this mouse model, with the aim of promoting pro-
inflammatory microglial death and as a consequence, drive remyelination after 
LPC-induced demyelination of the corpus callosum, for example. Conversely, in 
microglial-specific NFκB-deficient mice, is there less pro-inflammatory 
microglial activation and does this improve remyelination?   
Finally it would be important to determine the importance of microglial NFκB 
activation in the human context. By immunostaining of human MS tissue, it 
would be interesting to see if levels of NFκB activation in microglia is different 
in lesions with differences in remyelination potential. For example, in active 
lesions where efficient remyelination can take place, is there less microglial/ 
macrophage NFκB activity? This could potentially be measured by nuclear NFκB 
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staining compared to cytoplasm and comparing the ratio of nuclear: cytoplasmic 
NFκB localisation in microglia in different lesion types (co-staining with a 
microglia marker that outlines the whole cell such as IBA-1). Are there more 
NFκB+ microglia in lesions that fail to remyelinate (and where we know that 
there are less MLKL/RIPK3+ microglia and therefore potentially less death)? It 
may be that NFκB activity is high in all activated microglia regardless of 
phenotype and function, in which case we can look at different downstream 
NFκB-activated proteins to determine if there are differences in NFκB activity 





The aims of my PhD were to investigate the mechanisms that drive the 
activation of microglial phenotypes during efficient remyelination, with a 
particular focus in how microglia transition from an initial pro-inflammatory 
phenotype to a pro-regenerative phenotype at the onset of remyelination. My 
findings show that at the onset of demyelination, microglia rapidly activate to a 
pro-inflammatory phenotype, indicated by the expression of iNOS. IFN-γ/LPS 
treatment, used to induce a potent pro-inflammatory microglial response, is also 
associated with iNOS expression and production of TNF-α. Although only iNOS 
was used as a marker to identify pro-inflammatory microglia in my studies, 
iNOS expression has been associated with i) in	vitro microglia which do not 
support oligodendrocyte differentiation, ii) in	vivo microglia in focal 
demyelinated lesions which also express pro-inflammatory mediators TNF-α 
and CCL2, and iii) microglia in MS lesions which have poor remyelination 
potential (8). Indeed, persistent pro-inflammatory microglial activation is seen 
in models with poor regeneration such as spinal cord injury (SCI) (192,	208,	
257) and in response to demyelination in aged mice (147,	193), as well as being 
associated with lesions with a poor remyelination potential in MS (8,	100,	106,	
240,	242). Therefore, uncovering how microglial phenotypes are regulated 
during efficient remyelination could reveal promising new therapeutic avenues 
for remyelination in diseases like MS, of which there are no currently approved 
therapies. By focusing on the fate of iNOS+ microglia after demyelination, I 
observed that these cells underwent cell death shortly after their peak in 
activation in ex	vivo and in	vivo models of efficient remyelination. The 
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mechanism of cell death was identified to be necroptosis, characterised by 
expression of necroptosome protein RIPK3 and necroptosis initiator MLKL, and 
the reduction in cell death observed when necroptosis was blocked with small 
molecule inhibitor necrostatin-1. Although phosphorylated MLKL initiates 
oligomerisation with itself, leading to cell membrane pore formation and death 
via necroptosis (159), antibodies against pMLKL could not be optimised for our 
tissue, and this was therefore one limitation of my immunofluorescent analysis 
of necroptosis. Nevertheless, upregulation of RIPK3 and MLKL, reduction in pro-
inflammatory microglia counts after their peak in activation, and prevention of 
death with necrostatin-1 provided evidence to support that pro-inflammatory 
microglia undergo necroptosis during efficient remyelination.  
Microglial necroptosis then lead me to investigate how microglial repopulate, 
and leading to a subsequent peak in pro-regenerative microglial activation at 
the initiation of remyelination. Lineage tracing of both Nestin+ cells and 
Cx3cr1+ microglia showed that although the majority of repopulation appears 
to be via residual microglia, there are is small population of Nestin+ cells able to 
differentiate into microglia. With inducible Cre-based reporter systems, there is 
a level of spontaneous recombination that can occur, which differs with each 
reporter; spontaneous recombination was measured in explant cultures for 
both reporters prior to demyelination by fixing tissue without 4-OHT 
administration (and low levels of spontaneous recombination were observed in 
tdT(Nestin) slices, but not observed in tdT(Cx3cr1) slices (data	not	shown)). 
However, spontaneous recombination in	vivo, or after demyelination was not 
measured, and both would have been additional controls strengthening 
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evidence from the lineage tracing studies. For tdT(Nestin) lineage tracing in 
particular, where I saw a small percentage of Nestin+ cells that expressed 
CD11b and CD45 during repopulation in	vivo, it would be extremely important 
to analyse the levels of tdT(Nestin)+ CD11b+ CD45lo (used to identify microglia 
from peripheral macrophages in CNS tissue (CD11b+CD45hi)) cells at the same 
time point post-demyelination but without prior tamoxifen administration to 
rule out spontaneous recombination in microglia. Particularly as I have shown 
that residual microglia can express Nestin during repopulation, as have others 
(68,	70,	218), it would be important to show that these 
tdT(Nestin)+CD11b+CD45lo cells are not just microglia that have undergone 
spontaneous recombination. If this was the case, this would support the idea 
that residual microglia are the only source of repopulating cells after depletion, 
as is shown in other studies (68,	70). However, this would raise the question of 
the source of microglia repopulation in an experimental model with 100% 
microglial depletion; does repopulation still take place, or is there a non-
microglial source for repopulation in this case? Again this may depend on the 
method of depletion, and if the blood brain barrier is compromised. 
Furthermore, all depletion studies and my own study have neglected to 
investigate the role of peripheral macrophages in microglial repopulation. I 
have shown that Ccr2-RFP+ macrophages are present in the lesion site from 3 
dpl and are still present, albeit in lower numbers, at 10 dpl. Although no time 
points past 10 dpl were investigated, it would be important to know if 
peripheral macrophages persist in the brain after remyelination is complete and 
contribute to repopulation. Indeed, recent evidence suggests that bone marrow 
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derived macrophages are able to populate the CNS after partial microglial 
depletion (25% reduction in microglia by genetic ablation), are seen to be 
engrafted into the brain parenchyma even 12 weeks post-depletion and 
maintain a unique identify compared to resident microglia (221).  
I then aimed to determine if known immunomodulatory compounds could 
promote pro-inflammatory microglia to change phenotype, or if they could 
accelerate cell death. My findings showed that microglia loss occurred at 24 
hours with IFN-γ/LPS treatment, often used to induce a pro-inflammatory 
phenotype in microglia in	vitro (8), which was accelerated with co-treatment of 
17-β Estradiol, substance P, Rho kinase inhibitor HA-1077 and PPAR-γ agonist 
Rosiglitazone. Although an observed loss of microglia occurred, confirmation of 
cell death by propidium iodide for example, would prove this loss is cell death 
and not a loss of adhesion. Nevertheless, this preliminary evidence suggests the 
possibility that some immunomodulatory compounds may act by promoting the 
death of pro-inflammatory microglia, a previously unappreciated mechanism 
for immunomodulation. By using models associated with poor regeneration and 
persistent pro-inflammatory microglial activation, it will be interesting to see if 
such compounds can promote pro-inflammatory microglial cell death and if this 
is sufficient to promote pro-regenerative microglial activation and 
remyelination. However, compounds such as 17-β Estradiol that act on 
ubiquitous estrogen receptors will most likely result in many off-target effects 
and may need to be encapsulated for specific microglia-targeted delivery.  
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Finally, it will be important to determine if promoting microglial necroptosis is a 
viable treatment option for diseases like MS. By using the LPC-mediated focal 
demyelinating lesion model, we are able to look at demyelination and 
remyelination in isolation, and therefore the timeline of microglial activation, 
necroptosis and repopulation are consistent. However, in models with 
concomitant demyelination and remyelination, and with lesions in different 
phases of remyelination or demyelination, it may prove difficult to determine 
the correct timing for treatment. Nevertheless, if microglial depletion leads to a 
pro-regenerative microglial repopulation (202), this may still be a viable 
approach. Therefore, investigating if microglial necroptosis promotes recovery 
in more complex models of inflammation, demyelination and 
neurodegeneration may increase the translational relevance of this work and 






I have shown that pro-inflammatory microglial necroptosis is a feature of 
efficient remyelination which may represent a rapid approach to shut down 
inflammatory responses, allowing for the activation of pro-regenerative 
microglia that drive remyelination. After microglial necroptosis, repopulation 
takes place from two sources; residual microglia and Nestin+ cell 
differentiation. Furthermore, microglial necroptosis and repopulation are 
features of MS lesions with high capacity for remyelination, and blocking 
necroptosis experimentally leads to the inhibition of remyelination. Therefore, 
microglial necroptosis may be necessary for efficient remyelination to take 
place, and persistent pro-inflammatory microglial activation in models of poor 
regeneration and in human chronic inflammatory demyelinating diseases may 
reflect impaired microglial death. Targeting pro-inflammatory microglial 











 4-OHT: 4-hydroxytamoxifen 
 ALS: Amyotrophic Lateral Sclerosis 
 Arg-1: Arginase-1  
 ATP: Adenosine Triphosphate 
 BBB: Blood Brain Barrier 
 CNS: Central Nervous System 
 DAMPs: Damage-associated Molecular Patterns 
 DCX: Doublecortin 
 DT: Diphtheria toxin  
 E: embryonic Day  
 EAE: Experimental Autoimmune Encephalomyelitis 
 EMPs: Erythroid Myeloid Progenitors 
 EtOH: Ethanol 
 G.W.: Gestational Week 
 GdCl3: Gadolinium Chloride 
 GM-CSF: Granulocyte-macrophage Colony Stimulating Factor 
 HSCs: Haematopoietic Stem Cells 
 IDO: Indoleamine 2 3-dioxygenase 
 IFN-γ: Interferon Gamma  
 IGF-1: Insulin-like Growth Factor 1 
 IKK: inhibitor of NFκB kinase subunit 
 IL-: Interleukin 
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 iNOS: Inducible Nitric Oxide Synthase 
 iPSCs: Inducible pluripotent stem cells 
 IRF-8: Interferon regulatory factor 8 
 IκBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
 LPC: Lysophosphatidyl Choline  
 LPS: Lipopolysaccharide 
 MAG: Myelin Associated Glycoprotein 
 MALT1: Mucosa-associated Lymphoid Tissue Lymphoma Translocation 
Protein 1 
 MBP: Myelin Basic Protein 
 M-CSF: Macrophage Colony Stimulating Factor 
 MDMs: Monocyte-derived Macrophages 
 MHC: Major Histocompatibility Complex 
 MLKL: Mixed-lineage Kinase Domain Like Pseudokinase  
 MOG: Myelin Oligodendrocyte Glycoprotein 
 MRI: Magnetic Resonance Imaging 
 MS: Multiple Sclerosis 
 MSX3: Msh Homeobox 3 
 NAWM: Normal Appearing White Matter 
 NEMO: NFκB essential modulator 
 NFκB: Nuclear Factor Kappa Light-chain-enhancer of Activated B Cells 
 NPC: Neural Progenitor Cell 
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 OPC: Oligodendrocyte Progenitor Cell 
 PAMPSs: Pathogen-associated Molecular Patterns 
 PBMCs: Peripheral Blood Mononuclear Cells 
 PLP: Proteolipid Protein 
 PMD: Pelizaeus-Merzbacher Disease  
 PNS: Peripheral Nervous System 
 PPMS: Primary Progressive Multiple Sclerosis 
 RIPK: Receptor Interacting Protein Kinase 
 RRMS: Relapse-remitting Multiple Sclerosis 
 SCI: Spinal Cord Injury 
 SNr: Substantia Nigra Reticulata 
 SPMS: Secondary Progressive Multiple Sclerosis 
 TBI: Traumatic Brain Injury 
 TGF-β: Transforming Growth Factor Beta 
 TLR: Toll-like receptor 
 TNFR1: TNF-α Receptor 1 
 TNF-α: Tumour Necrosis Factor Alpha 
 TUNEL: Terminal deoxynucleotidyl tranferase dUTP nick end labelling 












Figure	2. Raw values from mice treated with vehicle (VEH) LNCs and 
necrostatin-1 (NEC) LNCs immunostained for Tmem119, iNOS and Arg-1 at 
195 
 
10dpl. Tmem119+ cells are represented as total counts. iNOS and Arg-1 are 
represented as a percentage of the total number of IBA-1+ cells expressing iNOS 
and Arg-1. 	 	
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